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Abstract
Congenital heart defects are responsible for the mortality of approximately 300,000
newborn each year. One study in 2010 estimated that over 2 million patients were living
with congenital heart defects in the United States. Congenital heart defects have the highest
hospitalization cost among other birth defect categories. The damage on the U.S economy
in 2013 was estimated $6.1 billion. The most complex and severe form of these defects
results in single ventricle physiology. Fortunately, over the last 50 years, these patients
have been able to survive into adulthood as a result of three stages of surgeries culminating
with Fontan operation.
However, Fontan operation as the current ultimate palliation of single ventricle
defects results in significant late complications. Fontan patients will eventually develop
circulatory failure and are in desperate need of an immediate therapeutic solution. A right-
sided device surgically placed in the cavopulmonary pathway could technically substitute
the missing sub-pulmonary ventricle by generating a mild pressure boost.
However, currently, there is no device specifically designed for this application due
to the small market size. On the other hand, off-label use of an arterial pump (originally
designed for left side application) for the cavopulmonary support remains challenging. This
is because the hemodynamic impact of a ventricular assist device (VAD) implanted on the
right circulation of a Fontan patient is not yet clear. Moreover, further research is needed to
identify the physiological consequences of two clinically-considered surgical configurations
ii
(IVC and full assisted configurations) for the cavopulmonary VAD installation, with full and
IVC support corresponding to the entire venous return or only the inferior venous return,
respectively, being routed through the VAD.
First objective of this thesis is surgical planning to accurately predict the outcome
of cavopulmonary support in failing Fontan patients and findings of this study will help the
surgeons in developing coherent clinical strategies for the cavopulmonary support imple-
mentation and tuning. Specific objective 2 will investigate the desired operating region for
designing a cavopulmonary blood pump that can offer a promising alternative treatment
option for a wide range of failing Fontan patients.
iii
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Chapter 1
Introduction
1.1 Background and Motivation
1.1.1 Single Ventricle Defect
Congenital heart defects are responsible for the mortality of approximately 300,000
newborn each year. One study in 2010 estimated that over 2 million patients were living with
congenital heart defects in the United States [8]. Congenital heart defect has the highest
hospitalization cost among other birth defect categories. The damage on the U.S economy in
2013 was estimated $6.1 billion [9]. The most complex and severe from of these defects can
results in single ventricle physiology. The single ventricle defect is a rare congenital heart
disease, however, it is highly complex. The birth incidence of congenital heart diseases is 4
to 50 in 1000 live births and approximately 8% of the patients with congenital heart diseases
are diagnosed with single ventricle defect (univentricular heart). The birth incidence of the
univentricular heart is approximately 4 to 8 in 10,000 live births [10].
A Normal heart has two ventricles; these ventricles generate the pressure gradient
for driving the blood flow into the circulatory system. However, one of the ventricles in
1
Figure 1.1: Diagram of normal biventricular heart and heart with HLHS. An HLHS heart
has one ventricle or the other ventricle exists but it is normally small and dysfunctional.
Photo placed into public domain by Mariana Ruiz.
a patient with Hypoplastic Left Heart Syndrome (HLHS) is severely underdeveloped and
not functional or does not even exist. Figure 1.1 illustrates the difference between a single
ventricle heart (HLHS) and a normal bi-ventricular heart.
In the HLHS circulation, the existing single ventricle pumps a mixture of deoxy-
genated (venous return from the superior vena cava and inferior vena cava) and oxygenated
blood (from lungs) to the entire circulatory system. For the survival of HLHS patients after
the birth, they need to undergo three stages of surgeries at different ages. These surgeries
are aimed to augment the blood oxygen level and unload the excessive blood volume on the
single ventricle. However, even after these surgeries, the mortality rate of these patients is
still very high; i.e. a two-year follow-up study [11] showed that after the stage 1 operation
(known as Norwood producer), a relevant number of the single ventricle patients will not
survive (≈40%). The second procedure is called bidirectional glen (or hemi-Fontan) and
the last stage is known as Fontan operation. Through each operation, more blood flow is
2
Figure 1.2: Diagram shows a single ventricle heart after staged operations. A) Single ven-
tricle after Norwood operation 1) A shunt that has been placed between subclavian artery
and the pulmonary artery. 2) Removal of the atrial septum 3) Pulmonary artery stump
4) the ascending aorta anastomosed to main pulmonary artery to create an unobstructed
pathway. B) After the Glen operation ≈6 months after birth. 1) The superior vena cava
detached from the right atrium and connected directly to the right pulmonary artery 2)
removal of the arterial shunt. C) Fontan procedure at 2-5 years of age. The inferior vena
cava is detached from the heart and anastomosed to the right pulmonary artery. 1) The
inferior vena cava connected to the right pulmonary artery. The entire venous return is now
directed to the lungs. 2) A fenestration that has been created to allow residual right to left
mixing. This diagram is from [4].
diverted to the lungs; following the Fontan producer, the entire venous return bypasses the
heart and flows directly to the lungs. After the Fontan completion, the SVC and IVC are
connected to the pulmonary artery according to figure 1.2.
1.1.2 Fontan Operation
Over the past 50 years, Fontan operation has been the most definitive palliative care
for patients with single ventricle defect. Currently, 50,000-70,000 patients worldwide exist
that have been able to survive because of the Fontan operation [12]. However, a significant
number of these patients will eventually develop circulatory failure as a result of the poor
hemodynamics following the Fontan procedure [13,14].
Although the single ventricle defect is rare, the annual estimated healthcare cost
3
surpasses $500 million [15]. Based on a 10 year follow up study, 1 out of 4 children after the
Fontan operation will not survive [14]. Failing stage in a Fontan circulation manifests itself
in a cascade of the pathological consequences such as protein-losing enteropathy, hepatic
failure, and gut dysfunction.
Previous clinical measurements [14, 16, 17] have recorded pulmonary arterial hy-
potension and high caval pressure (also known as “Fontan paradox” ) in single ventricle
patients after Fontan procedure. In fact, chronic high caval pressure is found to be the
main determinant of many Fontan-related diseases and circulatory failure [18]. Low pul-
monary pressure and attenuated pulmonary vascular pulsatility also underlie subnormal
pulmonary vascular resistance in Fontan patients [19].
The elevated pulmonary vascular resistance concurrent with low cardiac output in
Fontan patients are the key risk factors of the Fontan failure. Single ventricle patients fol-
lowing the Fontan operation also display signs of cardiac malfunction [20]. The progression
of the ventricular stiffness initiates early after the Fontan procedure possibly as a result of
preload depletion.
1.2 Research Motivation
Most Fontan patients are unable to receive a heart transplantation either because
they are poor candidates as a result of the previous several surgeries and multiple organ
dysfunctions or because of the unavailability of a matching organ donor. Mechanical assisted
device to propel the venous return forward into the lungs has been suggested as a solution
to reverse the Fontan paradox.
Conceptually, a device properly implemented in the cavopulmonary pathway could
generate a slight pressure boost that benefits the hemodynamics by lowering the caval pres-
sure and augmenting the cardiac output. Clinical application of the cavopulmonary device
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is most likely to happen in failing patients; these patients are in desperate need of an imme-
diate therapeutic solution. However, the right circulatory support is not currently
employed in the clinical management of the single ventricle patients because
there is currently no pump available in the market and regulatory approved
for this application. However, several pump prototypes has been introduced for cavopul-
monary support. Such a pump should be able to work in low pressure environment and be
able to serve failing Fontan population.
1.3 Dissertation Overview
This dissertation is organized as follows:
The second chapter of this dissertation, we investigate the off-label use of a ven-
tricular assist device as a cavopulmonary support. Also, this chapter presents two surgical
configurations for installation of a right support and evaluates how hemodynamic outcome
is different between these configurations.
Then, in the third chapter we present the criteria for designing a suitable cavopul-
monary support that can be used for serving a majority of the failing Fontan population.
In chapter four, we present a new hybrid computational-experimental framework
for testing medical products that captures closed-loop heart response to any change in the
experimental or computational model. This framework is called ”The Physiology Sim-
ulation Coupled Experiment” and capitalizes on the strengths of both computational
and experimental methods in a single model.
Finally, chapter 5 discusses the contribution of this dissertation and future direc-
tion.
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Chapter 2
Risks and Benefits of Using a
Commercially Available
Ventricular Assist Device for
Failing Fontan Cavopulmonary
Support [1, 2]
Further research is needed to compare the hemodynamics between the two clinically-
considered surgical configurations (Full Support and IVC Support) for cavopulmonary assist,
with Full and IVC Support corresponding to the entire venous return or only the inferior
venous return, respectively, being routed through the VAD. In this chapter, we used a numer-
ical model of the failing Fontan physiology to evaluate the Fontan hemodynamic response to
a left VAD during the IVC and Full supports. We observed that during the Full support the
VAD improved the cardiac output while maintaining blood pressures within safe ranges, and
lowered the IVC pressure to <15mmHg; however, we found a potential risk of lung damage
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at higher pump speeds due to the excessive pulmonary pressure elevation. IVC support the
other hand, did not benefit the hemodynamics of the example failing Fontan patients, re-
sulting in the superior vena cava pressure increasing to an unsafe level of >20 mmHg. The
findings in this study may be helpful to surgeons for recognizing the risks of a cavopulmonary
VAD and developing coherent clinical strategies for the implementation of cavopulmonary
support.
2.1 Overview
This study focuses on the cavopulmonary support scenario where a mechanical as-
sist device propels the venous return forward into the lungs as an attempt to reverse the
Fontan paradox. Conceptually, a pump properly implemented in the cavopulmonary path-
way could generate a slight pressure boost that benefits the hemodynamics by lowering the
caval pressure and augmenting the cardiac output. Earlier studies either have suggested
implementing the cavopulmonary device to directly pump the inferior vena cava (IVC) flow
to the pulmonary artery (“IVC assisted configuration”) [21–23] or proposed the “Fully as-
sisted configuration” to pump the entire venous return to the pulmonary artery [24, 25]
(Figure 2.1). Previously, Molfetta et al. [26] showed that an ideal cavopulmonary pump
could promote the cardiac output by 34% during IVC support. To our knowledge, there
has been no study that directly assesses how the hemodynamics compare between these two
surgical configurations for the installation of the cavopulmonary assist device.
A concerted work is in progress to develop a cavopulmonary assist device as a
bridge to cardiac transplantation or for long-term support. Researchers have suggested
several prototypes for powering the Fontan circulation [22, 27–30]. While these prototypes
are designed to be compatible with a low-pressure operating environment, they are not
commercially available and thus not employed in the clinical management of single ventricle
patients. As such, a relevant clinical question is whether an existing VAD originally designed
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Figure 2.1: Schematic representation of the surgical configurations for the cavopulmonary
assist installation. (A) Fully assisted configuration (Full support) and (B) IVC assisted
configuration (IVC support). LPA: Left pulmonary artery, RPA: Right pulmonary artery
SVC: Superior vena cava, IVC: Inferior vena cava.
for the left side application can be used as right-side support in a failing Fontan patient.
Therefore, the objectives of this study are 1) to identify the possible risks and ben-
efits of the off-label use of the Jarvik 2000 (or another left VAD with similar mechanical
performance) for IVC and Full support in adult failing Fontan patients, and 2) to assess how
the hemodynamics compare between the IVC and Fully assisted surgical configurations for
installation of the cavopulmonary assist device. We hypothesized that it is possible to use
a left VAD for the cavopulmonary application and to palliate the failing Fontan condition
albeit with potential risks. To test this hypothesis, we first performed a sensitivity analysis
on a lumped parameter network (LPN) model of the healthy adult Fontan physiology to
attain a quantitative understanding how different factors affect the Fontan circulation; next
we constructed a failing Fontan circulation model and simulated the IVC and Fully as-
sisted surgical configurations to determine hemodynamic aberrations of each configuration
at different pump speeds.
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2.2 Physiology model of the healthy Fontan circulation (base-
line)
A closed-loop LPN was employed to model the Fontan physiology (Figure 2.2).
A full description of the modelling protocol has been described in our previous work [5].
Briefly, the LPN can adjust model parameters such as cardiac function, vascular resistances,
vascular compliances, and respiratory parameters to simulate the hemodynamics of a Fontan
patient. The transmyocardial pressure (Psv) generated by the single ventricle drives the
flow in the circuit and is defined to be correlated with the ventricular elastance and volume
(Equations 2.1 and 2.2). The ventricular time-dependent elastance “E(t)” is defined as a
function representing ventricular filling and contraction.
Psv(Vsv, t) = E(t)(Vsv − Vsv0) (2.1)
E(t) = EmaxEn(
0.3
tsvs
t) + Eoffset (2.2)
t is the time point in the cardiac cycle. The systolic period is given by tsvs, where Vsv0
and Vsv are the ventricular reference volume and ventricular volume, respectively. En
is the normalized elastance function. Emax is related to the contractility and ventricular
ejection fraction. Eoffset reflects ventricular filling. The ventricular compliance is correlated
with ventricular filling and thus Eoffset is also considered as a measure of the ventricular
compliance.
In this study, we tuned the LPN models according to [5] to represent two healthy
adult example Fontan patients with a small and large body surface area (BSA) under resting
condition. The small patient has weight=50kg and height=150cm and the large patient has
weight=75kg and height=180cm.
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Figure 2.2: LPN model of the Fontan circulation coupled with the VAD describing either
the (A) Full Support or (B) IVC Support scenario. Pressure points (Psub) are labelled on
the diagram. Lsub and Rsub are inductor and resistor components, respectively. [5]
2.3 Sensitivity analysis
Most of the single ventricle patients following the Fontan operation display signs of
ventricular diastolic dysfunction and elevated pulmonary vascular resistance [19,20,31]. To
determine how ventricular diastolic dysfunction and pulmonary vascular resistance affect
hemodynamic parameters such as cardiac output, atrial pressure, and IVC pressure in a
failing Fontan circulation, we performed a sensitivity analysis using LPN simulations where
in each example patient we decreased the ventricular compliance by an amount from 0 to
75% and increased the pulmonary vascular resistance by an amount from 0 to 100% of their
baseline values with a step change of 25%. We maintained the ventricular contractility
at its baseline value because previous studies have shown that ejection fraction is mostly
preserved in the majority of failing and healthy Fontan patients [31–33].
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2.4 Physiology model of the failing Fontan circulation
A failing circulation is characterized by high pulmonary vascular resistance and low
cardiac output [18]. Increased pulmonary vascular resistance is partly attributable to low
pulmonary pressure and attenuated pulmonary vascular pulsatility in Fontan patients [19].
Clinical reports show that on average in a failing Fontan circulation, pulmonary vascular
resistance is elevated by 68% [18] and cardiac output is reduced by 40% [6,18] compared to
the healthy Fontan circulation.
Moreover, Hebson et al. [34] reported that adult failing Fontan patients had lower
systemic vascular resistance in comparison with asymptotic Fontan patients, possibly due
to the autonomic control maintaining the total vascular resistance. A previous report
showed that 73% of the Fontan patients also suffer from a decrease in ventricular compliance
(resulting in ventricular diastolic dysfunction) that initiates early after the Fontan procedure
possibly as a result of preload depletion [31].
To simulate the failing Fontan circulation based on these clinical findings, we first
increased the pulmonary vascular resistance by 68% from the baseline. Then, we reduced the
systemic vascular resistance to compensate for the elevated pulmonary vascular resistance
such that the total vascular resistance is maintained. Finally, we decreased the ventricular
compliance from the baseline to obtain a 40% reduction in the cardiac output emulating
ventricular diastolic dysfunction.
2.5 Model of cavopulmonary support
Using the failing Fontan LPN, we modelled the IVC and Fully assisted cavopul-
monary support configurations as shown in Figure 2.2. Two thirds of the left VADs im-
planted in patients in the USA are axial-flow VADs [35], many with similar hydraulic
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Figure 2.3: Blood pump characteristic curves. (A) Comparison of head curves of several
commonly used left VADs operating at their lowest rotor speeds vs the operating range of
the Jarvik 2000, and (B) Performance curves of the Jarvik 2000 blood pump at different
rotor speeds.
characteristics curves as the Jarvik 2000 (Jarvik Heart, Inc., New York, NY, USA). The
performance range of the Jarvik 2000 can encompass the characteristic curves of several
commonly used VADs operating at their lowest rotor speeds (Figure 2.3.A) [36,37]. There-
fore, we modelled the Jarvik 2000 as a representative VAD in this study.
The off-the-shelf operating range of the Jarvik pump is 8000-12000rpm. We modified
the off-the-shelf controller to achieve lower pump speeds down to 4400rpm, then performed
a series of physical flow experiments to characterize the blood pump (Figure 2.3.B). The
details of the flow experiments are included below. The pump model is presented in the
form of a 3rd order polynomial equation (2.3) [3, 38].
∆P = aQ3 + bQ2 + cQ+ d (2.3)
Where ∆ P [mmHg] is the pressure head across the pump and Q [mL.s−1] is the
flowrate through the pump ranging from 0 to 100 mL.s−1. a, b, c and d are constants
dependent on the pump speed (Table 2.1).
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Rotor speed (rpm) Coefficients
a b c d
4400 -0.1563×10−3 -0.002356 -0.1267 20.55
5500 -0.1181×10−3 -0.003486 -0.0711 30.83
7000 -0.1838×10−3 0.01323 -0.8355 56.91
8500 -0.1371×10−3 0.0106 -0.854 79.86
9500 -0.1627×10−3 0.02024 -1.511 107.2
Table 2.1: Coefficients for the Jarvik 2000 blood pump performance characteristic model
at different rotor speeds.
2.6 Physical Flow Experiments
We conducted several steady tests in the physical experiment to characterize the
Jarvik 2000 performance at different rotor speeds and to relate the flow through the pump
and corresponding ∆P. We fitted a 3rd order polynomial equation on each set of measured
flow and pressure data points at each rotor speed (Figure 2.3). Figure 2.4 shows the exper-
imental setup used for characterizing the Jarvik pump.
We used 40% glycerol solution as the working fluid due to its similar density (1092.4
kg/m3) and viscosity (0.004 Pa.s) to those of blood. For driving the working fluid and
generating a steady flow through the Jarvik pump, we used a gear pump as shown in Figure
S1. A clamp-on flow probe (9PXL, Transonic Systems, NY) and a flow meter (TS410,
Transonic Systems, NY) were used for monitoring the volumetric flow rate through the
Jarvik pump and rigid tubes. We measured the pressures at the inlet and outlet of the
Jarvik pump by inserting catheter pressure transducers through the small ports at those
locations. The pressure transducers were connected to a pressure box (PCU 2000, Millar
Instruments, TX) for collecting the pressure signals. We carried out the data acquisition by
using a compact DAQ chassis (NI cDAQ 9174, National Instruments, TX) with mounted
NI 9205 and NI 9263 modules (National Instruments, TX). The data were exchanged at a
sampling rate of 1kHz between a desktop computer (a costume MATLAB program) and
the physical experiment.
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Figure 2.4: Schematic representation of the physical experiment setup. This setup is used
to obtain the characteristics equations of the Jarvik 2000 at different rotor speeds. The
gear pump produces the steady flow. The pressure and flow sensors are placed downstream
of the pump to collect the signals.
2.7 Results
2.7.1 Sensitivity analysis
We quantified the sensitivity of the Fontan hemodynamics to variations in the pul-
monary vascular resistance and ventricular compliance (Figure 2.5). Both example patients
we simulated had a similar response to the sensitivity analysis. While the cardiac output
and atrial pressure were affected by both pulmonary vascular resistance and ventricular
compliance, they were more sensitive to the ventricular compliance. For every 25% decre-
ment in the compliance, the cardiac output decreased by 11% and atrial pressure increased
by 24%. For every 25% increment in the pulmonary vascular resistance, the cardiac output
decreased by 3%, and atrial pressure decreased by <2.5%. Moreover, the slope of the
lines at different levels of ventricular compliance indicated that the atrial pressure became
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Figure 2.5: Hemodynamic response of the large simulated patient to the variations in the
pulmonary vascular resistance (PVR) and ventricular compliance. CO: Cardiac output,
Pivc: IVC pressure and Psa: Atrial pressure.
slightly more sensitive to the pulmonary vascular resistance at lower ventricular compli-
ances. The IVC pressure is sensitive to changes in both the pulmonary vascular resistance
and the ventricular compliance.
2.7.2 Failing Fontan physiology
In our simulations, the hemodynamic parameters of a failing circulation were sig-
nificantly different from those of the healthy Fontan patients (Table 2.2 and Figure 2.6).
Compared to the baseline, the arterial pressure in the failing circulation was significantly
lower ( 30%); the clinical data reported by Cavalcanti et al. [6] and Egbe et al. [17] similarly
showed a 23% decrease in arterial pressure. The simulations indicated that the IVC pressure
elevated on average by 50% (6.5mmHg) in the failing Fontan patients comparing to the
baseline, also consistent with previous reports [6, 17, 34]. The atrial pressure substantially
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Parameters Baseline / Failing
Small patient Large patient
Height (cm) 150 180
Weight (kg) 50 75
BSA (m2) 1.44 1.94
Cardiac output (L.min−1) 3.56/2.14 4.71/2.86
Arterial pressure (mmHg) 89.44/63.10 87.64/61.69
Atrial pressure (mmHg) 8.00/14.62 7.46/13.45
Pulmonary pressure (mmHg) 12.29/18.90 11.66/17.88
IVC pressure (mmHg) 12.29/18.90 11.66/17.88
Table 2.2: Mean values of the hemodynamic parameters from simulations of the two example
Fontan patients at baseline and during Fontan failure.
Figure 2.6: Failing Fontan hemodynamics in comparison with the baseline. The averaged
hemodynamic data of two example failing Fontan patients were normalized with respect to
the baseline. Cardiac output (CO), arterial pressure (Pa), IVC pressure (Pivc), pulmonary
pressure (Ppul) and atrial pressure (Psa) are presented.
increased in the failing Fontan models by an average of 81%.
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2.7.3 Cavopulmonary support for the failing Fontan circulation (Figure
2.7)
2.7.3.1 Fully assisted configuration
The presence of the VAD increased the cardiac output and favourably decreased
the IVC pressure across all pump speeds for the small patient but only above 5000rpm for
the large patient. For the large patient with rpm <5000, the cardiac output and the IVC
pressure deteriorated and changed by -7.5% and +5.6%, respectively.
For both patients, the cavopulmonary VAD generally resulted in the reduction of the
superior vena cava (SVC) pressure. For every 1000rpm increase in the pump speed, the IVC
pressure decreased by 20% and the cardiac output improved by 10% on average. Higher
pump speeds (small patient: > 5500rpm, large patient: > 6800rpm) led to the elevation
of the pulmonary pressure level to >25mmHg, which is above safe physiological range [39].
Overall, the rpm values for improving cardiac output while maintaining pressures within
safe physiological range was between 5000-6800 for the large patient and 4400 to 5500 rpm
for the small patient.
2.7.3.2 IVC assisted configuration
While the IVC support augmented the cardiac output and led to a favourable de-
crease in the IVC pressure, the SVC pressure increased to above 20mmHg even at the
lowest pump speed (4400rpm) for both patients. The IVC pressure was highly sensitive to
the pump speed, continually decreasing with increasing pump speed.
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Figure 2.7: Comparison of hemodynamic parameters during Full and IVC support at differ-
ent rotor speeds. Simulation results of the (A) large patient and (B) small patient. Cardiac
output (CO), SVC pressure (Psvc), IVC pressure (Pivc), pulmonary pressure (Ppul).
2.8 Discussion
The Fontan procedure is currently the standard-of-care final procedure for the pal-
liation of single ventricle defects. However, Fontan patients are predisposed to circulatory
failure as a result of the abnormal hemodynamics. This study aims to evaluate the risks and
benefits of the off-label use of a left VAD during Full and IVC support in failing Fontan pa-
tients with diastolic dysfunction. Through simulations, we showed that a proper implemen-
tation of an arterial pump in the right circulation could benefit the Fontan hemodynamics.
We constructed the failing Fontan model employing clinical data available in the literature
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and found that the failing circulation model to be in general agreement with previous re-
ports [26,27,40]. Our model sensitivity analysis showed the association of the hemodynamic
parameters (e.g. cardiac output, IVC pressure, atrial pressure) with pulmonary vascular
resistance and ventricular diastolic dysfunction. The results of this analysis suggested that
the significant elevation of IVC pressure in a failing circulation reported in previous clinical
studies [6, 34] is equally attributable to the high pulmonary vascular resistance as well as
elevated downstream pressure related to ventricular compliance reduction. Furthermore,
deterioration of ventricular compliance had significant implications on the atrial pressure,
cardiac output, and central venous pressure; thus, it is important to include ventricular
diastolic dysfunction in failing Fontan circulation models. The sensitivity analysis indi-
cated that changes in the ventricular compliance and pulmonary vascular resistance had
considerable and minimal effects on atrial pressure, respectively. This implies that elevated
atrial pressure may be an indication of ventricular diastolic dysfunction in failing Fontan
patients. The sensitivity analysis also showed that ventricular diastolic dysfunction and
elevated pulmonary vascular resistance both decreased the cardiac output. Cardiac output
reduction and consequently further preload starvation most likely will result in additional
deterioration of the ventricular diastolic function [20,41] leading to a positive feedback loop
and eventually cardiac failure in failing Fontan patients. Therefore, augmentation of the
cardiac output is a crucial factor for the survival of these patients.
The utilization of the right-side circulatory device to promote the hemodynamics of
a failing Fontan is appealing; however, implanting the cavopulmonary device on the right
circulation is surgically complex. Implementation of the pump in a failing Fontan requires
additional invasive surgeries for taking down the venae cavae for cannulation. From a
surgical point of view, the Full assist configuration is relatively more invasive because of the
additional steps necessary for detaching and anastomosing both the SVC and IVC. However,
our simulations showed that IVC support had limitations. While surgical implementation
of IVC assist is perhaps less complex, the model revealed that the pressure generated by
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the pump even at the lowest speed was excessively high (7mmHg at 1.66 L/min of flow)
and resulted in elevation of the SVC and pulmonary pressure to above 22mmHg and out
of acceptable physiological ranges. Cerebral venous thrombosis, a result of elevated central
venous pressure, is frequent after the Fontan operation (occurring in 21% of patients) [42–
44]. Precipitous rise of the SVC pressure due to an IVC assist pump transmitted to the
cerebral venous circulation could further predispose the patient to thrombosis.
Shimizu et al. [23] reported that IVC assist is more suitable for Fontan cavopul-
monary support. They modelled a similar size example patient with weight=75 kg and
BSA=1.9 m2. The disparity between our conclusions is likely due to the differences in the
pump models employed and the cardiac function prescribed in the physiology simulations.
The pump model that they employed was more compatible with the low-pressure environ-
ment. This pump, although not currently commercially available, was capable of generating
smaller pressure boost at low flow rates (resulting in lower SVC pressure). Additionally,
their example patient had a normal ventricular diastolic function and consequently higher
IVC flow and cardiac output. Nonetheless, their study also confirmed that the elevation
of the SVC pressure by the presence of the pump is a major drawback of the IVC assist
configuration.
Risk of venous collapse is another important concern with the IVC assist configura-
tion while using a left VAD. Riemer et al. [21] observed the intermittent collapse of the IVC
and subsequent decrease in the IVC flow in animals after implementing a HeartMate II in
the IVC. Our simulation results also implied the possibility of venous collapse at the inlet
of the pump due to the very low IVC pressure at high pump speeds. On the other hand,
for the fully assisted configuration the caval pressure remained positive across all pump
speeds we examined; this result is consistent with the report by Gandolfo et al. [25] where
no venous collapse was observed after implanting the Jarvik 2000 on the right circulation
of four sheep using the Full Support surgical configuration.
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Although the risk for venous collapse was lower in Full support, the simulations
showed that over-filling of the Jarvik pump at low pump speeds was a major shortcoming
of this configuration. In the large patient and for pump speeds <5000rpm, the blood
pump obstructed the flow and resulted in a reduction of the cardiac output and undesirable
increase of the IVC and SVC pressure. However, in the small patient no pump over-filling
was observed due to the lower venous return flow rates.
During Full support, we were able to identify a range of the pump speed for each
example patient that resulted in improved hemodynamics. However, the optimal range was
outside of the off-the-shelf range of the Jarvik 2000 (i.e. 8000-12000rpm). While maintaining
all the pressure in the safe physiologic range, the cardiac output increased by up to 30%
at 5500rpm and 6800rpm for the small and large patients, respectively. The optimal pump
speeds depended on the specific hemodynamics of the failing patient and performance of
the pump. Therefore, subject-specific modelling is important for identifying suitable pump
speeds while investigating cavopulmonary assist.
2.8.1 Limitations
Currently, the cavopulmonary device is not employed in the clinical management of
Fontan patients, therefore the results of this study cannot be validated against clinical mea-
surements. Fluctuation in the rotational speed of the pump as a result of pulsatile flow has
been observed in our previous experimental study [33]; while the LPN model is not capable
of capturing these fluctuations, since the pulsatility in the pulmonary flow is low, these
fluctuations should not result in significant error in the simulated hemodynamic outcomes.
Another limitation of the current study is that the LPN model is not able to resolve vessel
wall shear stress, which is known to impact endothelial function and pulmonary vascular
resistance in Fontan patients. Finally, the numerical model is tuned based on clinical data
from adult patients [22], therefore the results should not be expanded to pediatric patients.
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2.9 Conclusion
The computational model we presented suggested that a cavopulmonary VAD can
benefit failing Fontan patients and that IVC assisted configuration is associated with higher
risks compared to Full assist. The proper adjustment of a cavopulmonary device depends on
the device characteristics and hemodynamic state of the patient; we therefore recommend
subject-specific modelling for identifying the pump speed range that would benefit the
patient. Future studies should focus on designing a blood pump that has the performance
requirements for cavopulmonary application. We showed that, theoretically, a modified left
VAD (Jarvik 2000) implemented in the right circulation can help failing Fontan patients.
However, further research is needed to examine the risks associated with the modification of
a left VAD to achieve lower pump speeds since such modifications can affect the reliability
and stability of the device. Other methods for reducing the pressure generated by the pump
such as trimming of the rotor blades [25] can also be further investigated in future studies.
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Chapter 3
Cavopulmonary Support Operating
Criteria for Serving the Failing
Fontan Population
This chapter aims to elucidate the hydraulic operating regions that should be tar-
geted for designing cavopulmonary blood pumps. By integrating numerical analysis and
available clinical information, the interaction of the cavopulmonary support via the IVC
and full assist configurations with a wide range of simulated adult failing patient cases was
investigated; with IVC and full assist corresponding to the inferior venous return or the
entire venous return, respectively, being routed through the device. We identified the de-
sired hydraulic operating regions for a cavopulmonary assist device by clustering all head
pressures and corresponding pump flows that result in hemodynamic improvement for each
simulated failing Fontan physiology. Results show that IVC support can produce beneficial
hemodynamics in only a small fraction of failing Fontan patients. Cavopulmonary assist
device could increase cardiac index by 28% and decrease the inferior vena cava pressure by
35% depending on the patient’s pre-support hemodynamic state and surgical configuration of
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the cavopulmonary assist device (IVC or full support). The desired flow-pressure operating
regions we identified can serve as the performance criteria for designing cavopulmonary as-
sist devices as well as evaluating off-label use of commercially available left-side blood pumps
for failing Fontan cavopulmonary support.
3.1 Overview
Recently, in addition to the traditional class of failing Fontan patients, a new failing
Fontan phenotype class with high caval pressure and normal cardiac output has been rec-
ognized [45,46]. Despite normal cardiac output, this failing Fontan class is sicker compared
to the traditional group, possibly due to more severe liver-related complications [47]. While
some researchers have found no association between Fontan related liver complications and
cardiac output [48], others have suggested liver fibrosis and hepatic arterialization as a cause
for the higher cardiac output in this group of failing Fontan patients [49].
The growing population of Fontan patients suffering from life-threatening late com-
plications signifies the importance of undertaking engineering and medical efforts to address
the unmet therapeutic need and ameliorate limitations of the Fontan circulation.
Cavopulmonary support for failing Fontan patients has been unsuccessful as a result
of hemodynamic differences between these patients [50].A suitably designed cavopulmonary
assist device should be versatile enough to serve a wide range of failing Fontan patients
with various levels of hemodynamic instability. The objective of this study is to identify
the desired operating regions for such a device in the setting of inferior vena cava (IVC)
and full assist surgical configurations.
In this study [51], we classified hemodynamic failure in Fontan patients into two
groups: 1) traditional failure with low cardiac output concurrent with chronic high caval
pressure and 2) failure with chronic high caval pressure concurrent with normal cardiac
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output. Each group encompasses physiologic cases with various hemodynamic states. We
developed numerical models to simulate a full range of failing stage Fontan physiologies
in each phenotype class reflecting pathological conditions with various severity levels of
systolic dysfunction, diastolic dysfunction, and abnormal systemic and pulmonary vascu-
lar resistances. The Fontan physiologic cases with different hemodynamic conditions were
modeled to represent at least 95% of patients in both failing phenotype groups. Next, a
cavopulmonary assist device generating a range of head pressure rises (from 0-30mmHg)
during full and IVC support was modeled for each physiologic case. In each simulated case,
we identified the pump head pressures and the resulting pump flows (P-Q data points) that
produce hemodynamic improvement, signified by reduced IVC pressure (most important)
and other desirable hemodynamic changes. Lastly, we identified the desired operating re-
gions for designing a cavopulmonary assist device suitable for the full or IVC support by
clustering all of the P-Q data points that resulted in hemodynamic improvement in all
simulated failing Fontan physiology.
3.2 Methods
3.2.1 Physiology model of the healthy Fontan circulation (Baseline)
In an earlier chapter, we used clinical and physiological data from healthy Fontan
patients to develop and validate a closed-loop lumped parameter network (LPN) model for
describing the healthy Fontan circulation (Fig. 3.1). Table 3.1 details the range of time-
averaged values of selected physiologic parameters of six healthy Fontan patients (baseline)
with various body sizes. The simulation are performed based on the assumption that these
six body sizes cover a broad range of the Fontan population. Parameters used for setting
the LPN component values for each patient at the baseline are derived according to our
previous study [5].
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Figure 3.1: Closed-loop lumped parameter model of the Fontan circulation. Con-
ceptual representation of the (A) Full support and (B) IVC support assist device coupled
to the LPN model of the Fontan circulation. R is cavopulmonary connection’s dynamic
resistance, Cavo-Device is cavopulmonary assist device, LPA is left pulmonary artery,
RPA is right pulmonary artery SVC is superior vena cava, IVC is inferior vena cava.
Pressure points (Psub) are labeled on the diagram. Lsub and Rsub are inductor and resistor
components, respectively [5].
3.2.2 Physiology model of patients with hemodynamic failure
There are several determinants which influence hemodynamic parameters such as
patient’s body size, cardiac function and the aberration level of systemic and pulmonary
vascular resistances. In this paper, we used the baseline model as a starting point for
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Table 3.1: Mean values of the hemodynamic parameters from simulations of the 6 example
Fontan patients at baseline.
Parameters Range
BSA (m2) [1.27-2.3]
Cardiac output (L.min−1) [3.37-5.79]
Arterial pressure(mmHg) [91.98-97.10]
Atrial pressure(mmHg) [8.90-9.92]
Pulmonary pressure (mmHg) [13.37-14.50]
IVC pressure (mmHg) [13.37-14.50]
building physiology models of patients in the failing stage. This was achieved by adjusting
the component values corresponding to the pulmonary and systemic vascular resistances as
well as the systolic and diastolic ventricular functions. To include a wide range of patient
cases for each phenotype group, for each of the six patient body size baseline models, we
simulated different physiologic cases with different level of pulmonary and systemic vascular
resistances and severity of systolic and diastolic dysfunctions. The structure of the LPN
circuit is not affected by these changes, only the component values are. Ohuchi et al. [7]
and Cavalcanti et al. [6] have evaluated the hemodynamics in adult failing Fontan patients
and presented a broad range of clinically measured physiologic values of cardiac index and
arterial and IVC pressures for failing patients as mean value with 1 standard deviation
(SD). We modeled physiologic cases in each phenotype class such that the range of sim-
ulated scenarios (e.g., cardiac index, arterial pressure, IVC pressure) cover approximately
2SD of those clinically measured parameter values; based on the three-sigma rule, 2SD from
the mean value encompasses ≈95% of the population values [52].
3.2.2.1 LPN Model of Group I phenotype (Failing patients with high caval
pressure and low cardiac output)
This phenotype is well recognized. The circulation in this class of patients generally
deteriorates as a result of systolic dysfunction, diastolic dysfunction, and high pulmonary
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vascular resistance [7, 46, 53]. Therefore, we simulated this phenotype by reducing ventric-
ular contractility (Emax, representing ventricular systolic function), increasing ventricular
stiffness (Eoffset, representing ventricular diastolic function) and increasing pulmonary vas-
cular resistance (PVR). These values were incrementally changed to model various severity
levels of hemodynamic aberration according to the following protocol:
1) The range of Emax was defined to start at the baseline value and end at the value
that results in an ejection fraction of 30% [26] (this corresponds to a specific cardiac out-
put).
2) While Emax was held constant at its baseline value, the range of Eoffset was defined to
start at the baseline value and end at the value that results in the cardiac output obtained
at the end of step (1).
3) Similarly, while Emax and Eoffset were maintained at their baseline values, PVRs´ range
was defined to start at its baseline value and end at the value that results in the cardiac
output obtained at the end of step (1).
4) A number of equally spaced levels for each input variable (PVR, Emax, Eoffset) over
their ranges, as determined in steps (1-3), were used in all possible permutations to simulate
a wide range of possible failing physiologic cases.
5) Next, selected physiologic parameters (IVC pressure, cardiac index, and arterial pres-
sure) from each simulated case were evaluated against clinical catheterization data from
failing Fontan patients reported by Cavalcanti et al. [6].
The simulated cases where the selected physiologic parameters fall outside of approximately
2SD of the mean value of the clinical catheterization data were discarded. This resulted in
500 simulated patient cases for group I.
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3.2.2.2 LPN Model of Group II phenotype (Failing patients with high caval
pressure and normal cardiac output)
To our knowledge, there exists currently no mathematical circulation model available
for this group. The pathophysiology related to this class of patients is not well understood.
While the cardiac function in this group of patients is normal, the systemic vascular re-
sistance (SVR) is abnormally low. Moreover, contrary to the traditional group of failing
Fontan patients, the pulmonary vascular resistance in these patients is often low [46]. To
simulate this class of Fontan failures, we decreased the systemic and pulmonary vascular
resistances over a wide region from their baseline values while maintaining normal ventric-
ular systolic and diastolic function. There is limited information on the level of systemic
and pulmonary vascular resistance aberration in this recently recognized group of failing
patients. Therefore, we investigated the SVR and PVR values in our models such that the
selected physiologic parameters from simulations cover 2SD of the mean value of the clinical
data through the following steps:
1) The region of interest of SVR was defined to start from its baseline value (SVR0) and
end at 10% of SVR0. 10 equally spaced levels for SVR over its region of interest were taken.
2) The region of interest of PVR was defined to start from its baseline value (PVR0) and
end at 20% of PVR0 . 10 equally spaced levels for PVR over its region of interest were
taken.
3) Similar to the procedure used for group I, we compared the simulated physiologic cases
in group II with clinical data from group II failing patients reported by Ohuchi et al. [7]
and removed physiologic cases that were outside of 2SD of the mean value of the clinical
data. These steps resulted in 281 simulated patient cases for group II.
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3.2.3 Cavopulmonary assist device implementation (Fig. 3.1)
We modeled the implementation of the cavopulmonary support via IVC and full
assist surgical configurations. The graphic in Fig. 3.1 is for the purpose of illustrating the
blood routing concept of the IVC/full support configurations, not as a geometric surgical
guide for device placement. In a realistic clinical scenario, the implant will most likely be
extracorporeal.
The dynamic flow resistance of the surgical junction geometry is flow-related. There-
fore, a variable resistance is added to the LPN model as shown in Fig. 3.1 to estimate the
dynamic changes in this resistance value as a result of pump-induced flow augmentation.
The details of the experimental setup for characterizing the value of this dynamic resistance
are included in the Appendix A.
3.2.3.1 Model of full assist configuration (Fig. 3.1A)
In this configuration, the pump is implemented such that it drives the entire venous
return to the lungs. Implanting the pump would require performing a Fontan ”takedown”
and additional surgeries for anastomosis of the superior vena cava (SVC) and IVC conduit;
this implies that both vena cavae are at the pump’s inlet, having the same blood pressure.
For the purpose of illustration, Fig. 3.1A shows a potential configuration where an extra
conduit connects the cavopulmonary device between the vena cava and the pulmonary
artery.
3.2.3.2 Model of IVC assist configuration (Fig. 3.1B)
In this configuration only the IVC flow passes through the pump. The IVC pump is
implemented in series with the Fontan baﬄe and the pump’s inlet and outlet are connected
to the IVC and the right/left pulmonary arteries confluence in the LPN circuit, respectively.
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The zero-dimensional LPN model does not contain spatial information, therefore, the TCPC
junction being at the same node as the SVC shares an equal blood pressure; and the IVC
shares the same pressure as the pump’s inlet.
3.2.4 Desired operating regions for cavopulmonary assist device
Overall, 781 (500 for group I + 281 for group II) different patient cases were sim-
ulated. For each patient case and with the full and IVC assist surgical configurations, we
simulated device head pressure rises from 0-35mmHg in 0.5mmHg increments. Overall,
approximately 110,000 (781 patients cases×2 configurations×70 head pressure rise values)
simulations were carried out to obtain the desired operating regions. The algebraic and or-
dinary differential equations obtained from the LPN models were solved using Runge Kutta
method programmed in Fortran. Simulations were carried out for 30 seconds to ensure that
all flows and pressures in the LPN circuit stabilize. All results we report in this paper reflect
the stabilized state.
High caval pressure is the main determinant of Fontan related diseases. Thus, for
each simulated case, the head pressures and the resultant corresponding pump flows that
led to a decrease in the caval pressure while maintaining other physiologic pressures in
safe ranges were identified. Hemodynamic improvement was defined as at least 3mmHg
decrease in the IVC pressure while maintaining a pulmonary pressure <25mmHg [54] (to
avoid pulmonary arterial hypertension and lung perfusion damage), an atrial pressure of
<16mmHg, [55] SVC pressure <20mmHg (to avoid precipitous increase in the SVC pressure
and potential cerebral damage), and mean IVC pressure >4mmHg (to avoid potential IVC
collapse). Finally, the data points corresponding to the head pressures and pump flows
that resulted in hemodynamic improvement in each physiologic case were clustered to form
the desired operating regions. The flow diagram (Fig. 3.2) summarizes the process for
identifying the desired operating regions.
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Figure 3.2: Flow Diagram illustrating the procedure for obtaining a desired operating region.
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Figure 3.3: Hemodynamics of failing Fontan patients from simulation vs. clinical
data. Range of the selected hemodynamic parameters (pre-support) from simulations and
reported catheterization data [6, 7] of the group I and II failing Fontan physiologic cases.
CI: cardiac index, IVC pressure: inferior vena caval pressure, SD: Standard deviation.
3.3 Results
3.3.1 Patients with hemodynamic failure
Comparing the simulation results against the catheterization information reported
in Cavalcanti et al. [6] for group I and Ohuchi et al. [7] for group II of Fontan failures, the
range of selected physiologic parameters for the simulated cases encompasses approximately
a 2SD range of the values of those parameters measured clinically in Fontan failures in group
I and II (Fig. 3.3).
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Figure 3.4: Target flow-pressure regions for designing cavopulmonary supports.
Desired operating regions of (A) IVC and (B) full assist cavopulmonary devices suitable
for serving a wide range of failing Fontan patients in group I and II phenotype classes.
3.3.2 Desired operating regions for cavopulmonary assist device
We obtained the desired head pressure–flow operating regions of the IVC and full
cavopulmonary assist supports that properly serve a wide range of failing Fontan patients
in each phenotype class (Fig. 3.4). Depending on the patient’s class (group I or group II)
and surgical configuration for installation of the cavopulmonary assist, a device should be
designed such that its characteristic curves at different pump speeds can encompass the
entire desired operating region. Our results show that during full support for group I and II
populations, the head pressure generated by the cavopulmonary device should not exceed
16mmHg and 14mmHg, respectively. During IVC support, the head pressures required are
smaller than 11mmHg and 12.50mmHg for group I and II, respectively.
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Figure 3.5: Pre-support hemodynamics of simulated patient cases that favorably
responded to cavopulmonary supports. Range of selected hemodynamic parameters
(pre-support) of physiologic cases characterized as group I (Solid lines) and group II (Dashed
lines) that favorably responded to the IVC and full cavopulmonary support.
We identified the simulated physiologic cases in each phenotype group that the
presence of the cavopulmonary pump can lead to hemodynamic improvement (Fig. 3.5).
Full support did not benefit either group if the patient’s pre-support IVC pressure 19mmHg.
Also, IVC support did not benefit group I and group II patients if the pre-support IVC
pressure was >17mmHg and >18.5mmHg, respectively. Additionally, IVC support did
not benefit group II patients if the pre-support cardiac index were >3.50L.min−1.m−2 or
<3.20L.min−1.m−2.
IVC support benefited significantly less physiologic cases comparing to the full sup-
port resulting in a smaller operating region (e.g. IVC support had beneficial hemodynamic
outcome in only 6 simulated group I physiologic cases).
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Figure 3.6: Cavopulmonary support hemodynamic impact. Response range (%) of
the selected hemodynamic parameters of simulated physiologic cases to the IVC and full
cavopulmonary support. CI: Cardiac index; Pivc: IVC pressure; Ppul: Pulmonary pressure;
Psa: Atrial pressure; Psvc: Superior vena cava pressure .
3.3.3 Hemodynamic response to cavopulmonary support.
Based on simulation results for the physiologic cases that favorably responded to
the cavopulmonary support, the presence of the cavopulmonary assist promoted the cardiac
index, pulmonary pressure and decreased the IVC pressure (Fig. 3.6). Furthermore, the
cardiac index increase was 15-35% (9-16%) for group I and 10-28% (7-18%) for group II
via full support (IVC support). The IVC pressure as a crucial parameter, also favorably
decreased across both groups by the presence of the cavopulmonary assist. Overall, the
maximum favorable reduction of the IVC pressure was ≈45% and ≈46% via full support
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and IVC support, respectively. The IVC pump increased the SVC pressure, whereas the
SVC pressure decreased via full support.
3.4 Discussion
The present study aimed to identify the desired operating regions for a cavopul-
monary blood pump that can support the failing Fontan circulation. These results can
assist manufacturers in designing a right side assist device suitable for IVC or full sup-
port surgical configurations and for different classes of Fontan failures. To obtain these
operating regions, a numerical analysis was performed investigating the interaction of a
cavopulmonary assist device with a broad range of the possible failing Fontan physiologic
cases.
In this study, cavopulmonary support in two groups of failing Fontan patients was
investigated. These patients’ hemodynamic conditions depend on several factors, includ-
ing systemic and pulmonary vascular resistances, and the cardiac performance which vary
widely between these patients. Both groups of the patients have high caval pressure and
previous studies have shown that many of the Fontan related complications are linked to
chronically high caval pressure [18]. However, the patients with a combination of normal
cardiac index and high caval pressure have worse long-term survival in comparison with the
traditional group based on clinical experience [47]. Liver injury is significantly correlated
with high caval pressure and the abnormally low systemic vascular resistance in these pa-
tients is hypothesized to be because of liver complications. The reduced afterload in this
group of patients significantly contributes to the cardiac index level. Even though these
patients have normal cardiac output and do not need cardiac output augmentation, the
presence of a cavopulmonary device can reduce the caval pressure and may alleviate liver
dysfunction [24].The hypothesis that reversing the liver damage can potentially stabilize
the systemic vascular resistance and cardiac output requires further investigation.
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Several studies have shown that a suitable cavopulmonary assist device could ben-
efit the hemodynamics by decreasing the IVC pressure and promoting the cardiac out-
put [16,27,29,56–64]. In another computational study, Shimizu et al. [23] also confirmed a
reduction of the IVC pressure and increase of cardiac output by the presence of a cavopul-
monary assist device in the IVC. Molfetta et al. [26] simulated the physiology of 10 failing
Fontan cases (group I) and quantified an average of 34% increase in the cardiac output
with an IVC support device. However, our results show a narrower range of cardiac output
increase in group I population with a maximum increase of 16% when comparing with pre-
vious studies; this is likely due to the flow-related surgical junction dynamic resistance that
was not accounted for in previous studies. In the IVC assist configuration, the dynamic
resistance of the TCPC junction resulted in significant pressure drop across the cavopul-
monary connection and increase of the SVC pressure which limited the beneficial effects
of the pump. Our results also show that both failing phenotype groups better responded
to full assist device (Fig. 3.6). On the other hand, IVC assist better performed in the
simulated group II patients and benefited only a limited number of group I cases (Fig. 3.5
and 3.6). Previous pioneering studies on short term Fontan animal models have highlighted
the importance of designing a proper mechanical assist device for right side support by rec-
ognizing the problems such as IVC collapse associated with off-label use of a left VAD for
cavopulmonary application [21,30,65]. For example, Riemer et al. [21] investigated the im-
pact of the right support using a left VAD (Thoratec HeartMate II, Thoratec Corporation,
Calif) in 8 sheep and they observed decrease of the IVC flow as a result of IVC collapse and
low IVC pressure (-0.25±0.48mmHg) in all animals. In an earlier study [2], it was shown
that there are risks associated with using a commercially available left ventricular assist
device (VAD) for cavopulmonary support in single ventricle patients. The pressure level in
the cavopulmonary pathway is approximately 90% lower compared to the left side arterial
environment; a left VAD typically generates a head pressure of ≈37 to 80mmHg for flow
rates ranging approximately from 0.5 to 6L.min−1. The high head pressure produced by a
left VAD implanted on the right circulation may result in pulmonary arterial tree perfusion
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damage, central venous collapse [16], cerebral edema or venous thrombosis.
We studied the two most clinically envisioned surgical configurations for the instal-
lation of the cavopulmonary assist device (IVC and full support) [23] and identified a range
where hemodynamic improvement is possible for each patient case via full or IVC support.
The optimal operating point for each patient lies in this range; therefore a full or IVC
cavopulmonary device should be capable of covering the corresponding range to provide
maximal adjustment flexibility to clinicians for obtaining the optimal operating point for
any patient. Simulations show that a proper cavopulmonary device for the traditional group
of failing Fontan patients (group I) only needs to cover a small operating region. However,
for the newly recognized phenotype group, the desired operating region covers a larger area
that may complicate the design of a cavopulmonary device.
There are other possible configurations for installation of the cavopulmonary assist.
For instance, Jagani et al. [66] proposed a dual-headed intravascular cavopulmonary pump
for installation in the SVC and IVC. In this case, the entire venous return is pumped to
the lungs and it is conceptually identical to the extracorporeal full support case. Cavopul-
monary assistance in the SVC is not a suitable option for three reasons: 1) most late Fontan
pathophysiology emerges from the the IVC distribution (liver diseases, protein losing en-
teropathy,etc) [16]; 2) a SVC pump would further increase the pressure in the opposing
venous territory (IVC); and 3) the majority of the systemic venous return is carried by the
IVC.
Trusty et al. [50, 67] studied installation of VentrioFlo Tru Pulse Pump, PediMag
and CentriMag in parallel with the Fontan baﬄe and observed significant recirculation of
the blood flow through the Fontan pathway. The majority of the flow recirculated from
the outflow cannula, down through the Fontan baﬄe and back into the inflow cannula of
the pump. Trusty et al. [50] argued that the hemodynamic influence of the recirculation
phenomenon depends on the amount of the device’s flow output. They showed that to
39
achieve hemodynamic improvement using the PediMag device, it is essential to constrict the
Fontan baﬄe to limit the blood flow recirculation through the pump; however, this resulted
in a detrimental increase in the SVC pressure. Whereas, while using the CentriMag pump (a
stronger device with greater output) the recirculation was beneficial for 3 reasons: 1) there
was no need for banding the Fontan baﬄe 2) there was no increase in the SVC pressure,
and 3) the recirculation actually entrained both the IVC and SVC flow which allowed both
vena cavae pressures to decrease while increasing pulmonary arterial pressure.
Nevertheless, banding of the Fontan baﬄe or recirculation caused by the capvopul-
monary pump could significantly increase thrombosis risks [68], therefore not a desirable
option.
The results of our current study can also be used to evaluate the performance of the
available cavopulmonary prototype devices as well as off-label use of commercially available
left VADs for cavopulmonary applications. Researchers in recent years have investigated
several cavopulmonary devices for supporting the failing Fontan circulation. Throckmorton
et al. [22] proposed an intravascular blood pump for the IVC support configuration. As
the intravascular blood pump (at 4000rpm) generates a pressure increase of 2.5-9.5mmHg
for the flows rates of 2-6L.min−1, its performance curve covers parts of the IVC support
desired operating regions (Fig. 3.7) which suggests that this intravascular cavopulmonary
blood pump at 4000rpm can serve some of the failing patients. The characteristic curve of
the Jarvik 2000 at 5500rpm [3] lies entirely outside of the full support’s desired operating
region (Fig. 3.7). Therefore, the Jarvik 2000 at this speed is not a suitable candidate for full
cavopulmonary support. However, at higher speeds ir can serve some of the failing patients.
Limitations
Factors such as the TCPC configuration and geometry have influence on the target
device operating. We fully recognize that differences in the surgical junction geometry can
affect the dynamic resistance and the obtained cavopulmonary support operating regions.
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Figure 3.7: Evaluating off-label use of available VADs (or proposed cavopul-
monary device prototypes) for right-side support application. Desired operating
regions of (A) IVC and (B) full assist cavopulmonary devices overlaid with characteristics
curves of a left VAD and a cavopulmonary intravascular blood pump.
There exist currently no information in the literature about the dynamic change in the
resistance of full support’s surgical junction geometry as a result of the pump-induced flow
augmentation; therefore, we assumed the same dynamic resistance for both IVC and full
support surgical junctions (Supplementary Material). Further studies are needed to predict
the flow resistance in the full support’s surgical junction geometry; The difference can be
compensated with increasing to decreasing the required head pressure. Furthermore, the
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geometry of the TCPC junction can affect the hepatic flow distribution [66,69] which is not
captured by the LPN model. Computational fluid dynamic simulations can be performed
to carefully investigate the change in the hepatic flow distribution as the result of different
Fontan geometries in the presence of a cavopulmonary assist.
We believe that cavopulmonary support will result in positive remodeling of the
vasculature leading to a reduction in pulmonary vascular resistance. However, the goal of
our current models is to focus on acute physiologic outcomes rather than long-term adap-
tation of the pulmonary and systemic vascular resistances as a result of the cavopulmonary
support. Our models also do not include fenestration that is present in some of the pa-
tients. However, the fenestration most likely would be surgically removed if cavopulmonary
support is to be implemented.
3.5 Conclusion
This study presents the hydraulic operating regions for manufacturing a cavopul-
monary blood pump specifically designed for helping failing Fontan patients. We simulated
and investigated the interaction of a cavopulmonary assist device (generating head pres-
sure from 0 to 35mmHg) with a full range of failing stage Fontan physiologies reflecting
pathological conditions with various severity levels of systolic and diastolic dysfunction and
abnormal pulmonary and systemic vascular resistances, representing approximately 95% of
the adult failing Fontan population. The results show that a cavopulmonary assist device
could increase cardiac index by 7-35% and decrease the IVC pressure up to 46% depending
on the patient’s pre-support hemodynamic state and surgical configuration of the cavopul-
monary assist device (IVC or full support). For the newly recognized failing class of Fontan
patients with normal cardiac output and high IVC pressure (group II) both IVC and full
assist support can be beneficial. For this group, an IVC assist device should be able to cre-
ate head pressures of 5-12mmHg for flows of ≈3.50-8L.min−1. However, the cavopulmonary
42
device should cover a wider range for both groups when providing full support( 3.7B). The
full support desired operating region shows the full assist pump should be able to produce
a head pressure of 6.5-16mmHg for flows of 3.50-8L.min−1 and ≈5.50-14mmHg for flows of
4.50-10.00L.min−1 for group I and II, respectively.
Additionally, we identified physiologic cases where cavopulmonary support cannot
benefit hemodynamic conditions, but rather predisposes these physiologic cases to perfusion
lung damage or venous collapse as a result of the pressure generated by the cavopulmonary
device. These phys- iologic cases were excluded and were not used for obtaining the de-
sired operating regions. These results may help serve as guidelines for identifying patient
characteristics unsuitable for cavopulmonary support.
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Chapter 4
A Hybrid Experimental-
Computational Modeling
Framework for Cardiovascular
Device Testing [3]
Significant advances in biomedical science often leverage powerful computational and
experimental modeling platforms. We present a framework named physiology simulation
coupled experiment (“PSCOPE”) that can capitalize on the strengths of both types of plat-
forms in a single hybrid model. PSCOPE uses an iterative method to couple an in vitro mock
circuit to a lumped-parameter numerical simulation of physiology, obtaining closed-loop feed-
back between the two. We first compared the results of Fontan graft obstruction scenarios
modeled using both PSCOPE and an established multiscale computational fluid dynamics
method; the normalized root-mean-square error values of important physiologic parameters
were between 0.1% and 2.1%, confirming the fidelity of the PSCOPE framework. Next,
we demonstrate an example application of PSCOPE to model a scenario beyond the cur-
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rent capabilities of multiscale computational methods—the implantation of a Jarvik 2000
blood pump for cavopulmonary support in the single-ventricle circulation; we found that
the commercial Jarvik 2000 controller can be modified to produce a suitable rotor speed for
augmenting cardiac output by approximately 20% while maintaining blood pressures within
safe ranges. The unified modeling framework enables a testing environment which simulta-
neously operates a medical device and performs computational simulations of the resulting
physiology, providing a tool for physically testing medical devices with simulated physiologic
feedback.
4.1 Literature Review
4.1.1 Current state of cardiovascular computational and in-vitro methods
The lumped parameter models have been used to simulate cardiovascular systems
since 1960s [70–73]. These computational models along with in-vitro models are less expen-
sive and non-invasive methods in comparison with human and animal trials for development
of medical devices and products. The lumped parameter models depending on the accuracy
can provide the opportunity for thorough analysis of the hemodynamic and physiologic
parameters in the cardiovascular systems.
Multiscale models have integrated the lumped parameter physiology models with
finite element models (Figure 4.1a) to simulate three-dimensional and complex dynamics of
the structures with moving components or static geometries [74–77].
On the other hand, in-vitro mock models offer the advantage to directly test medical
devices and capture complex phenomena that cannot be captured by computational models.
But, these in-vitro models have limitations in capturing changes in the preload and afterload
as a result of closed-loop response of the heart. Additionally, in-vitro models have difficulties
in achieving realistic end diastolic and end systolic pressure-volume features of the ventricles
45
Figure 4.1: Overall structure of a (a) numerical multiscale simulation and (b) hardware-in-
the-loop hybrid model. The PSCOPE framework is a high-fidelity implementation of the
hardware-in-the- loop hybrid modeling approach.
[78–82].
Despite significant progress in experimental and numerical techniques for investi-
gating the cardiovascular systems, there is currently no technique that capitalizes on the
advantages of both computational and experimental techniques in a unified and hybrid
framework.
4.1.2 The Hardware-in-the-Loop Technique
The Hardware-in-the-Loop (HIL) technique provides the opportunity to combine
a computational model of physiology with an in-vitro experiment. This method has the
potential to capitalize on the advantages of both computational and in-vitro experimental
models in a hybrid framework (Figure 4.1b).
The HIL was applied in 1992 [83] for the first time for cardiovascular modeling
and later other researchers [84, 85] built HIL models containing an actuator to mimic the
ventricular function. This actuator was controlled based on the the desired ventricular
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pressure that was calculated in real time using a lumped parameter physiology model. This
HIL method is also used to test ventricular circulatory devices under steady-flow conditions.
Moreover, other researchers [86–90] have used the HIL approach for modeling the
scenarios containing experimental sections in the proximity of aortic arch. For instance,
previously, an HIL model containing an experimental model of aortic valve was presented.
In this HIL model, the actuator was designed to be controlled based on the pressure across
the aortic valve. The pressure across the aortic valve was considered as the interface between
the experimental section and computational physiology domain of the HIL model.
Using HIL technique is possible to achieve the dependence of the mocked ventricular
pressures on ventricular contractility, preload or other factors. However, there are limita-
tions associated with the HIL approach. As a result of physical and mechanical limitations
of real time control of actuators and sensor measurements such as signal qualities, the HIL
is not a practical approach for investigating cardiovascular systems.
Previous researcher as mentioned above, have used the HIL for scenarios with in-
terfaces near the ventricle. In these scenarios the high amplitudes of the input and output
signals such as pressure, flow and actuator signals allow for tolerating the signal errors.
However, in low pressure environments these errors are significant, rendering the hybrid
model unusable.
4.1.3 The Physiology Simulation Coupled Experiment
In this chapter, we introduce the ”Physiology Simulation Coupled Experiment”
(PSCOPE) framework. The PSCOPE framework is capable of addressing the limitations
of the previous cardiovascular HIL models. By capitalizing on the periodic nature of the
physiologic pressure and flow, this framework uses an iterative approach to reduce the
physical and mechanical limitations in an HIL model such as signal delays and noises.
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In this chapter, we demonstrate the implementation of the PSCOPE framework.
Furthermore, we will apply the PSCOPE framework to model a scenario that its computa-
tional modeling is very complex. The PSCOPE provides the opportunity to experimentally
investigate a scenario that is complex for computational modeling (i.e., scenarios involving
fluid–solid interactions).
4.2 Physiology Simulation Coupled Experiment Coupling Prin-
ciple
The dynamic data exchange between the numerical domain and the experimental
section in an hybrid model has to be compatible with the operation of each domain. In an
HIL model, the real time exchange of the data occurs at each time step of the computational
simulation. This time step is very small (≤0.001s) and therefore the response time of the
experimental section’s components such as flow sensors, pressure sensors, and hydraulic
equipment need to be stringent. Additionally, The numerical model with a very small time
step requires that input and output data from the experimental domain to the numerical
simulation must be noise free and precise to avoid errors in the gradient and numerical
calculations.
The iterative PSCOPE framework allows signal conditioning in the experimental
section. We demonstrate the concept of the PSCOPE coupling framework using a scenario
containing a rigid experimental section with one inlet and one outlet and a simple numerical
domain (LPN model). The LPN model is represented by two ordinary differential equations
(4.1) and (4.2).
dP1
dt
=
1
C1
(
Pi − P1
R1
−Q
)
(4.1)
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dP2
dt
=
1
C2
(
Q− P2
R2
)
(4.2)
Psub, Q, Csub, and Rsub are the pressures, flow rate into the element, capacitance
and resistance values and are shown on Figure 4.2a. For any different combination of the
capacitance and resistance values, and a given initial pressure values (P1 and P2), and a
periodic pressure source (Pi) there exists a periodic solution for P1 and P2. Also, there
exists a unique flow (Q) that satisfies both the governing equations in the numerical model
(Equations (4.1) and ( 4.2 )) and the actual measurements across the physical experiment.
To implement the information exchange between the domains on a cycle-to-cycle
basis, we iteratively improve the entire Q waveform until the correct solution is identified.
Based on equations (4.1) and (4.2) in the numerical model, a specific Q waveform returns
a specific ∆P waveform where ∆P=P1-P2, which we refer to as ∆Pnum. Applying the
same Q waveform in the physical experiment and measuring the pressure drop across the
region of interest, we obtain another ∆P waveform, referred to as ∆Pexp. The Q waveform
corresponding to the correct solution of this coupled hybrid model is expected to produce
∆Pnum=∆Pexp.
By identifying this correct Q waveform, we achieve a direct coupling between the
experimental and numerical domains, forming a closed-loop PSCOPE model. In other
words, this method matches the boundary conditions between the numerical model and
the experiment by ensuring that, at the boundary interface, the flow and pressure drop
in the experiment match those in the numerical model. This general coupling approach is
applicable to PSCOPE models consisting of any complex lumped parameter circuits.
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Figure 4.2: (a) Schematic of an example PSCOPE model. Rsubscript and Csubscript
are resistance and capacitance values, respectively. Psubscript represent pressures at the
corresponding locations and Q is the volumetric flow rate through the physical experiment.
(b) Overall structure of the protocol for identifying the solution Q waveform coupling the
experimental and numerical domains. ((c)–(e)) Convergence of the PSCOPE model solution
in a scenario containing a realistic numerical physiology model and a physical Jarvik 2000
blood pump operating at 5000 rpm. (c) The Q waveform initial estimate is updated and
improved across iterations. (d) The difference between the ∆Pnum and ∆Pexp waveforms
decreases with iterations. (e) The decreasing residual errors between ∆Pnum and ∆Pexp
show the convergence of the PSCOPE model over iterations.
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Figure 4.3: Mathematical surrogate of the physical experiment. An example of the math-
ematical surrogate representing the behavior of the Jarvik 2000 pump operating at 8500
RPM. A series of steady flow measurements of flow rate through the pump (Q) versus
pressure rise across the pump (∆Pexp) provide the data for creating the best-fit regres-
sion curve. This mathematical surrogate enables the temporary conversion of the hybrid
PSCOPE model to a purely numerical model for deriving the initial estimate of the solution
flow waveform. Note that the surrogate model is specific to a particular rotational speed of
pump operation.
4.3 Iterative Solution Identification
We designed a protocol (Figure 4.2b) to identify the correct Q waveform solution
while minimizing the number of iterations required. To obtain a good initial guess for
Q, we first utilize a mathematical surrogate to approximate the behavior of the physical
experiment (see Figure 4.3).
A series of steady flow tests are conducted in the physical experiment to relate the
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flow through the experiment and ∆Pexp; for a physical experiment with multiple outlets,
this is repeated to relate the flow and ∆Pexp between the inlet and each outlet. An appro-
priate mathematical equation is chosen and fitted to each set of measured flow and ∆Pexp
data. Temporarily replacing the physical experiment with the mathematical surrogate, the
hybrid model converts to a purely numerical model, allowing a computational simulation
to be performed to obtain an initial estimate for the Q waveform (Figure 4.2c “Initial”).
Next, an iterative algorithm adjusts the Q waveform repeatedly (Figure 4.2c) based on
the differences between the resulting ∆Pnum and ∆Pexp waveforms (Figure 4.2d), contin-
ually decreasing the residual which is quantified by the normalized root-mean-square error
(NRMSE) between ∆Pexp and ∆Pnum (Figure 4.2e).
This iterative method is analogous to the nonlinear iterations in a numerical finite
element simulation for the continual improvement of the solution until an acceptable residual
is obtained. Specifically, the Q waveform is iteratively adjusted according to the following
equation:
Qn+1 = Qn +KP (∆Pexp −∆Pnum) (4.3)
Qn, Qn+1, and Kp represent the Q waveform of the current iteration, the adjusted
Q waveform for the next iteration, and the controller gain, respectively. The value of Kp
is optimized to avoid oscillations in the Q waveform (Kp value too high) or a very slow
progression of waveform adjustments between iterations (Kp value too low). To identify the
threshold for the optimal Kp value for a specific PSCOPE, we gradually increase Kp until
oscillation in the Q waveform occurs. This process does not require significant time as the
system’s response to each Kp value can be observed within just a few iterations. Once a
suitable Kp is identified, we iteratively update the Q waveform according to equation ( 4.3
) until the residual plateaus or falls below a user-specified tolerance.
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Figure 4.4: Setup of the physical hydraulic experiment Schematic and photographs of the
physical experiment setup.
4.4 Experimental setup
The working fluid in the flow experiments is a 40% glycerol solution with measured
density (1092.4 kg/m3) and dynamic viscosity (0.0041 Pa·s) similar to those of blood. A
custom computer programmable gear pump[1] capable of generating precise pulsatile flow
waveforms drives flow through the experimental section via rigid tubing. Volumetric flow
rate is monitored by an external clamp-on ultrasonic flow sensor (9PXL, Transonic Systems,
NY) positioned immediately upstream of the experimental section and connected to a flow
meter (TS410, Transonic Systems, NY). For pressure waveform measurements, we inserted
catheter pressure transducers (MPR-500 Mikro-Tip, Millar Instruments, TX) through small
ports at the inlet and outlet of the experimental section. The catheter pressure transducers
connect to a pressure control conditioner (PCU 2000, Millar Instruments, TX) by catheter
interface cables (PEC-10C/D, Millar Instruments, TX). Separate modules (NI 9205 and
NI 9263, National Instruments, TX) mounted on a compact DAQ chassis (NI cDAQ 9174,
National Instruments, TX) and interfaced via a custom Matlab program communicate the
signals of the experiment with a desktop computer at a sampling rate of 1kHz (Figure 4.4).
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For the purpose of measuring the real-time power usage of the Jarvik 2000 blood
pump, we placed a 1 Ohm resistor (1% tolerance) in series with the power supply cable of
the pump controller, and measure the voltage drop across the resistor to calculate current
draw. We then measure the voltage across the positive and negative terminals of the
pump controller power supply in order to calculate power consumption by the equation
Power=Voltage×Current.
4.5 Data analysis
To improve the signal-to-noise ratio in the pressure and flow measurements, we
average 23 cycles of each data acquisition and pass the resulting signal through a 40Hz
low pass filter (Figure 4.5). All experimental waveforms shown in the main body of the
paper are this 23-cycle averaged and filtered waveforms. Since the physiology simulation
uses a zero-dimensional model that does not consider wave propagation, we perform signal
alignment to remove the wave propagation delay between the inlet and outlet pressures
before coupling the data to the physiology simulation (Figure 4.5C). The sampling rate of
1kHz in the experiment is sufficient for capturing the delay time ”τ” which is typically in
the range of ≈5 ms. The definition we employ for the NRMSE between two waveforms “x1”
and “x2” is.
NRMSE(x1, x2) =
RMSE(x1, x2)
max(x2)−min(x2) (4.4)
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Figure 4.5: Experiment signal processing (A) An example of 25 cycles of raw data acquired
from the flow meter; the blown up portion shows 1 cycle of the raw data. Two initial
cycles from each acquisition are discarded and the rest 23 cycles are averaged. (B) The
resulting flow waveform after averaging and passing through a low-pass filter with a cutoff
frequency of 40Hz. (C) Synchronization of the inlet and outlet pressure signals by removing
wave propagation delay. This is essential for achieving proper coupling with the physiology
simulation which uses a zero-dimensional model that does not consider wave propagation.
The delay time ”τ” is typically in the range of ≈5 ms.
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4.6 Physiology Simulation
The physiology simulations in this study utilize a previously published lumped pa-
rameter network (LPN) of the single-ventricle circulation [23]. The specific parameter values
are detailed in Table 4.1 and 4.2.
The changes in intra-thoracic pressure due to respiration directly affect central ve-
nous blood flow, therefore, the respiratory cycle in the physiology simulation defines the
periodicity of the PSCOPE. Each respiratory cycle contains four cardiac cycles; the word
“cycle” in this paper refers to the respiratory cycle unless otherwise specified. On the con-
trary, the word “iteration” in this paper refers to each time the Q waveform is updated to
improve the solution.
4.6.1 Implementation of the Physiology Model
The LPN contains blocks that represent the heart, pulmonary circulation, several
internal organs, legs, and major blood vessels such as the abdominal aorta and IVC. Vascular
resistance, compliance and momentum of blood are modeled using resistance, capacitance
and inductance elements, respectively.
The transmyocardial pressure generated by the ventricle is described as , where and
represent ventricular reference volume and ventricular volume, respectively. E(t) is the
de-normalized time-varying elastance function given by:
E(t) =

EmaxEn(
0.3
tsvs
t) + Eoffset :
t
tsvs
≤ 3.33
Eoffset : elsewhere
(4.5)
t is the time point in the cardiac cycle; tsvs is the systole time period; and En is
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Table 4.1: Parameter values for physiology simulations Complete list of parameter values
for the LPN model describing 1 and 5 MET conditions in a Fontan patient with height of
150 cm and weight of 50 kg[3]. Resistance and inductance component values correspond
to those labeled in the closed-loop LPN figure in chapter 1. Capacitor component values
correspond to the capacitors adjacent to the labeled pressures in the closed-loop LPN figure
in chapter 1.
Resistance
(mmHg.s.ml−1)
Constants
(All MET Levels)
MET Level 1 MET 5 MET
Kao
(mmHg.s2.ml−2) 0.35
Ruba 0.686 0.686
Kav
(mmHg.s2.ml−2) 0.225
Rubv 2.398 2.398 Vsao(ml) 15
Rtha 0.081 0.045 Dsa (ml−1) 2.3×10−5
Raba 0.62 0.345 Psar (mmHg) 1.15×10−5
Rlega 1.52 0.194 MET Level 1 MET 5 MET
Rlegc 3.596 0.461 HR (bpm) 80 129
Rlegv 0.838 0.107 Emax 2.375 4.255
Rabv 0.059 0.059 Eoffset 0.199 0.135
Rthv 0.029 0.029 Vsvo -3.29 -3.292
Rla 8.578 8.578 APith -3.9 -19.5
Rlv 0.053 0.053 Pithoffset -3.7 3.98
Rka 6.042 6.042 Time Period (s)
Rkv 0.566 0.566 tsvs 0.275 0.231
Ria 13.247 13.247 tsas 0.247 0.208
Riv 0.24 0.24 t1 0.15 0.092
Rpa 0.023 0.018
Inductance
(mmHg.s2.ml−1)
Rpv 0.119 1.94 All MET Levels
Rsvc 0.059 0.059 Lav 11×10−6
Capacitance
(ml.mmHg−1) Llega 13.32×10
−4
Ck 1.978 1.978 Ltha 13.32×10−4
Cp 1.57 1.94 Laba 13.32×10−4
Csvc 1.57 1.57 Luba 5.48×10−4
Cub 3.375 3.375
Capacitance
(ml.mmHg−1)
Cao 0.549 0.549 MET Level 1 MET 5 MET
Ctha 0.164 0.255 Clegv 7.85 7.85
Caba 0.348 0.541 Cabv 7.85 7.85
Clega 1.541 1.541 Cthv 0.785 0.785
Ci 1.182 1.182 Cl 4.751 4.751
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Table 4.2: Initial values for physiology simulations.List of initial pressure values (mmHg) for
the LPN model describing 1 and 5 MET conditions in a Fontan patient with height of 150
cm and weight of 50 kg. The pressure nodes correspond to those shown in the closed-loop
LPN figure. Values for the initial flow through inductors do not affect the final simulation
results and thus are not included in the table.
1 MET 5 MET
Psvc 13.2 20.4
Pub 79.4 68.7
Pao 94.4 76.5
Ptha 92.6 75.3
Paba 92.6 64.6
Plega 66.2 56.2
Plegv 22.1 32.5
Pabv 13.2 27.9
Pthv 13.2 25.7
Pl 9.7 25.9
Pk 17.6 29.7
Pi 9.7 26.1
Pp 7.9 16.6
the normalized elastance function[2,3]; Emax and Eoffset are constant parameters to be set
for each simulation, and represent measures of ventricular contractility and compliance,
respectively. The transmyocardial atrial pressure, “Psa”, is modeled as
AA(t) =

1
2 [1− cos (2pi t−t1+tsastsas )] : t ≤ t1
1
2 [1− cos (2pi t−t1−tsadtsas )] : t1 + tsad ≤ t < tc
0 : elsewhere
(4.6)
In this equation t1 = 0.2tc and tsas = 0.9tsvs. The active and passive pressure are
simulated using following equations:
Psa,passive =
Vsa − Vsa0
Csa
(4.7)
Psa,active = Psar(e
Dsa(Vsa−Vsa0) − 1) (4.8)
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Where Vsa is the atrial volume and Vsa0 is the atrial volume at zero pressure. Csa,
Dsa, and Psar are constants. and The overall pressure generated by the atrium is given by:
Ptsa(Vsa, t) = Psa,passive + Psa,activeAA(t) (4.9)
The blood flow rates through the atrial-ventricular valve (Qav) and through the
aortic valve (Qao) are described as
Q˙av =
 0 : Psa < Psv and Qav ≤ 0Psa−PsvkavQ2av
Lav
: elsewhere
(4.10)
Qao =
 0 : Psv < Pao1
2Kao
√
4kao(Psv − Pao) : Pao ≤ Psv
(4.11)
Pao is the aortic pressure and Kao, Lav, and Kav are constants characterizing the
aortic and atrial-ventricular valve characteristics.
Intrathoracic pressure (Pith) variation due to respiration affects blood pressure in
the heart and in large blood vessels of the thorax, therefore, Pith is connected to the relevant
elements in the LPN. We approximate Pith using a cosine waveform as
where APith and Pithoffset are constants describing the amplitude and offset of the
thoracic pressure waveform. t is the time point in the respiration cycle; tr is the length of
the respiration time period and is given by tr= 4tc. Tables 4.1 and 4.2 list the complete LPN
parameter and initial values for simulating an adult Fontan patient with height=150cm and
weight=50Kg under resting (1 MET) and moderate exercise (5 MET) conditions[3].
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Figure 4.6: Effect of different initial guesses on the final solution Three different initial
guesses of the flow waveform (A) converge to the same final solution (B) after 3, 15, and 12
iterations for case 1, 2, and 3, respectively. The maximum RMSE between the final solutions
derived from each of the initial guesses is 0.66 mL/s. The PSCOPE scenario modeled here
is the 85% stenosis geometry coupled to the 5 MET physiology.
4.7 Results
Various initial guesses for the solution Q waveform converge to the same final solu-
tion, although requiring different number of iterations (see Figure 4.6).The PSCOPE shows
the changes in selected physiologic parameters as motor speed of the Jarvik 2000 is manu-
ally adjusted in the experimental domain (Figure 4.7). As we increased the rotor speed, the
cardiac output and pulmonary pressure increased. However, the IVC pressure decreased as
the rotor speed increased.
A pulmonary pressure higher than 22mmHg is clinically considered unsafe. While
the Jarvik 2000 can favourably increase the cardiac output at normal operating rotor speeds,
the pulmonary arterial pressure and superior vena cava (SVC) pressure become too high.
Also at normal speeds, the IVC pressure decreases significantly and the Jarvik 2000 could
result in the venous collapse (negative IVC pressure). However, by hacking into the off-
the-shelf pump controller, we achieved a pump speed suitable for Fontan right support at
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Figure 4.7: An example application of the PSCOPE for modeling a scenario beyond the
current capabilities of numerical simulations; the PSCOPE captures the closed-loop in-
teractions between the physical experiment involving the Jarvik 2000 and the simulated
physiology. (a) Mean values of important physiologic parameters corresponding to different
pump rotor speed settings show favorable physiology at approximately 5000 rpm, below
the normal operating range of the commercial device. ((b) and (c)) Detailed results at
pump speed setting of 5000 rpm; data from one respiratory cycle (four cardiac cycles) are
shown. (b) Ventricular pressure–volume loops show increased preload, stroke volume, and
aortic pressure with cavopulmonary support compared to the reference case without pump
support. (c) The physical operation of the Jarvik 2000 is impacted by physiologic rhythms
as the device power consumption fluctuates with the changing IVC flow throughout the
cardiac and respiratory cycles.
around 5000 rpm. At this rotor speed, all physiologic pressures such as pulmonary, SVC
and IVC pressures remain within safe ranges. Also, cardiac output, stroke volume and
systolic pressure are augmented by 14%, 16%, and 13%, respectively in comparison with
pre-support scenario(Figure 4.7b). The measured power consumption of the Jarvik 2000
during the respiratory cycle indicates that operation of the pump is impacted by physiologic
rhythms.
The solution of the PSCOPE in this case converged to a residual of 1.9% within 17
iterations, requiring a total run time of 1.8 h. In general, each PSCOPE iteration requires
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5-10 min of run time; of this, the computation time is negligible and most of the run
time is spent on data acquisition and the fine-tuning of actuation control in the physical
experiment.
4.8 Discussion
In this study, we introduced the PSCOPE framework that combines and capitalizes
on the strengths of numerical and experimental modeling platforms. The main advantage of
the PSCOPE framework is that it can experimentally model scenarios that are challenging
for computational simulations(i.e., Scenarios with moving components and complex geom-
etry, or fluid–structure interactions) and completely couples the experimental results with
a physiology simulation (which is challenging to produce experimentally) .
The design of the PSCOPE framework features a modular perspective toward the
physical experiment, where it is treated as a black box with inputs and outputs. Therefore,
the framework is valid for any physical experiment exhibiting a consistent behavior (i.e., a
specific combination of inputs produces a specific combination of outputs). The PSCOPE’s
modular nature also makes it immediately compatible with a range of physiology models
such as those incorporating auto regulation [91] or patient-specific tuning.
Moreover, Because of the lack of the real time requirement of the PSCOPE frame-
work, the equipment bandwidth limitation has minimal restraint on systems that can be
modeled and that compatibility with complex numerical techniques ( such as 3-dimensional
simulations) is feasible.The PSCOPE is completely different from fixed-input in-vitro mod-
els.
In PSCOPE the flow condition in the hydraulic experiment dynamically interacts
with the numerical physiology simulation through closed-loop coupling. This is useful in
cases where it may be difficult to precisely identify device operating characteristic when
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it dynamically responds to physiology. For example, a ventricular assist device operating
in pulsatile mode or surgically located in places where blood flow is highly pulsatile may
possess hysteresis in its pump speed and pressure-flow characteristics. In such cases, closed-
loop coupling between the experimental section and physiology simulation is needed to
achieve the right flow condition for the blood pump under test.
Our method to coupling the experimental domain and numerical domain involves
an iterative technique that inherently requires the explicit evaluation of the solution quality
and the iterative improvement of the solution to satisfy a predetermined residual. This
characteristic of the PSCOPE framework addresses the technical shortcomings of previous
HIL models and successfully achieves a accurate hybrid model. Due to the iterative char-
acteristic of the PSCOPE framework, the sensor measurements are processed to remove
the interfering signals and improve the signal to noise ratio. The PSCOPE also allows to
remove effects of delays due to the physical wave propagation, signal chain, , or actuator
bandwidth limitation as well as errors due to actuator non-linearity.
4.8.1 Limitations
The time needed for implementation of the PSCOPE for a scenario is the main
limitation of the PSCOPE framework. However, compared to the computational modeling
of the similar scenario, the PSCOPE run time is less. For experimental sections with more
inlet and outlets the number of iterations to find the flow solution will increase and ac-
cordingly the PSCOPE run time will increase as well. The factors that affect the PSCOPE
run time include the number of the signal averaging needed for increasing signal qualities
(sensor measurements and actuator response) of the hydraulic experiment. The predeter-
mined residual and the nature of the experiment also affect the PSCOPE run time and the
number of iterations needed for identifying the flow solution.
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4.9 Conclusion
While this study shows the application of the PSCOPE framework on modeling a
system with periodic nature, the framework ican be used for modeling transient responses.
This would need repeating the same experiment with the same initial conditions several
times to decrease signal noise and improve the signal, then employing the iterative method
we introduced to couple the cleaned experimental results with the physiology simulation.
In such a scenario, the the model execution run time is significant because the solution
waveform is lengthy.
Current in vitro methods are capable of investigating a variety of medical devices
including pulsatile blood pumps, valves, stents, balloons, and occlusion devices, all of which
can be physically implemented as part of a PSCOPE model; albeit physical experiments
containing deformable sections or multiple outlets will require the development of a more
capable waveform identification algorithm.
As physiology simulations continue to advance, the PSCOPE can enable cardiovas-
cular devices to be physically tested in vitro with physiologic feedback as if implanted in
a living patient. Since the bench top physical experiment is coupled directly in-the-loop
with a computational physiology simulation, it operates in a dynamically changing feedback
environment with the physiology simulation. This allows one to obtain the same relevant
information such as device operation and physiologic impacts as if performing an in vivo
human experiment.
Potential applications of the PSCOPE in interventional planning and clinical deci-
sion support may also help advance a variety of cardiovascular procedures. For example,
in addition to further investigations of blood pumps for Fontan cavopulmonary support,
we plan to extend the application of PSCOPE to study the efficacy and outcomes of tran-
scatheter pulmonary valve replacement procedures. Continued advancements and validation
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of the available physiology models as well as clinical validation of the predictions made by
the PSCOPE are critical issues that need to be addressed before clinical translation of this
tool.
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Chapter 5
Summary of the Dissertation
This chapter presents the concluding remarks for this dissertation and recommen-
dations for future research.
5.1 Summary of Contributions
The research in this dissertation is concentrated upon development of an ideal
cavopulmonary assist device for failing Fontan population. To achieve the dissertation
objective:
In chapter 2, we investigated hemodynamic implication of two different configura-
tions for surgical installation of a right-side support. The contributions are:
1. IVC surgical configuration is not a suitable surgical option for the installation of a
right-side support for a big fraction of failing Fontan patients.
2. Over-filling and obstruction of the cavopulmonary pathway can occur during full sup-
port and when using a left ventricular assist device for the right-support assist.
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3. It is imperative to design a circulatory device that is compatible with low pressure
environment of the cavopulmonary pathway.
In chapter 3, the target operation criteria for the design of a Fontan cavopulmonary
mechanical support device is proposed. The contribution are:
1. This study presents the hydraulic operating regions for manufacturing a cavopul-
monary blood pump specifically designed for helping failing Fontan patients.
2. The results show that such a cavopulmonary assist device could increase cardiac index
and decrease the IVC pressure.
3. The proposed operating regions can be used to evaluate the performance of the avail-
able cavopulmonary prototype devices as well as off-label use of commercially available
left ventricular assist devices for cavopulmonary applications.
4. The results may help serve as guidelines for identifying patient characteristics unsuit-
able for cavopulmonary support.
In chapter 4, a new approach for testing medical products is proposed. The contri-
bution are:
1. We present a framework named physiology simulation coupled experiment (PSCOPE)
that can capitalize on the strengths of both types of platforms (computational and
experimental methods) in a single hybrid model.
2. This framework mitigates the physical limitations in the hydraulic experiment such
as signal noises and delays.
3. It allows for the direct evaluation of the solution quality, guaranteeing the convergence
of the solution below a known residual.
67
4. It allows to experimentally investigate a scenario that is challenging for numerical
simulations (i.e., fluid-structure interactions) and fully couple the experimental results
with a physiology simulation (which is challenging to produce experimentally).
5.2 Recommendations for Further Research
Considering the direct correlation between the health of endothelial cells and pul-
satility of the physiologic flows and pressures, we propose implementing a pulsatile blood
pump in the cavopulmonary pathway to obtain a better hemodynamic outcome. Our sim-
ulations revealed that while the average magnitude of the pulmonary flow and pressure
improved by the presence of the cavopulmonary device, the pulsatility of the pulmonary
arterial pressure and flow significantly decreased.
The proposed hybrid framework in chapter 4 has a limitation and it is only suitable
for experimental sections with rigid boundaries. Further research is needed to address this
deficiency.
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Appendix A Cavopulmonary Connection Dynamic Resistance
During IVC and Full Support
A.1 Introduction
Implementation of the cavopulmonary support in Fontan patients will result in in-
creased blood flow through the cavopulmonary connection. Previous researches have shown
that the caval flow collision in a TCPC junction results in significant energy loss [1]. The
changes in this resistance as the result of augmented flow induced by cavopulmonary sup-
port may be significant and should be included in the simulations to obtain more realistic
physiologic trends. Therefore, we performed a series of steady flow tests and characterized
this resistance at different flow rates in the IVC support surgical junction geometry.
A.2 IVC support geometry
We assumed an idealized IVC geometry (Fig. A.1) and physically reproduced the
3D-geometry using a high resolution 3D printer (Connex 350 PolyJet, Stratasys, Inc., Eden
Prairie, MN). Phantoms were rapid prototyped using rigid material (VeroClear, Stratasys,
Inc., Eden Prairie, MN). We performed steady flow tests, data acquisition, and signal
processing as described below.
A.3 Experimental setup (Fig.A.2)
We used a glycerol solution (60% water and 40% glycerol) as the working fluid in the
setup. The density of the fluid and dynamic viscosity of the working fluid are 1092.4 kg.m−3
and 0.0041 Pa.s, respectively; similar to those of blood. A steady-flow pump was used to
drive the flow through the flow loop and the flow rate was controlled using a mechanical
valve. Volumetric flow rate was measured using a external clamp on ultra sound flow sensor
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(12PXL, Transonic systems, NY). The pressure at different locations were measured using
catheter pressure transducers attached to a pressure unit conditioner (PCU2000, Millar
Instruments, TX). We used separate NI modules for data acquisition (NI 9205, NI 9263,
National Instruments, TX). We collected the data at a sampling frequency of 1000 HZ. All
signal were passed though a 40 Hz low-pass filter for noise canceling. We measured the IVC
resistance at different cardiac outputs by comparing the flow rates through each geometry
with the corresponding pressure changes (∆P = R×Q, where R is resistance, P is pressure,
and Q is flow). Then, we fitted a linear line with adequate goodness-of-fit (r2=0.99) between
the resistance values and corresponding cardiac outputs.
A.4 Results
we estimated the total resistances across the TCPC geometry against the cardiac
output (CO) as follows:
R [mmHgL
min
] = 0.1234 × (CO [ Lmin ])+0.1101
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Figure A.1: Geometry of physical phantom. LPA is left pulmonary artery, RPA is right
pulmonary artery SVC is superior vena cava, IVC is inferior vena cava.
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Appendix B Verification of the Physiology Simulation Cou-
pled Experiment Framework
The verification of previous hybrid models has primarily been by method of compar-
ing results to physiologic data in the literature to identify agreement. These comparisons
have indicated the potentials of the HIL hybrid framework for creating physiologically real-
istic models. However, without a precise verification standard, the detriments of actuator
response time limitation, feedback signal delay, and measurement noise propagating in an
HIL setup are unknown and a rigorous verification of the model fidelity is lacking. There-
fore, in this section we present a quantitative verification of PSCOPE model results compared
directly against established multiscale simulation results.
B.1 Physiology Simulation Coupled Experiment Verification Setup
To quantitatively verify the results from PSCOPE, we model a scenario involving
a static experimental section such that the existing, established computational multiscale
methods [24,25] are capable of simulating and providing the actual model solutions. We
examine the scenario involving an obstruction of the Fontan graft in the cavopulmonary
pathway, clinically occurring due to deposition of calcium in the conduit and/or somatic
growth and subsequent longitudinal torsion of the graft [26]. The Fontan graft obstruction
geometry coupled to the physiology simulation is modeled using both PSCOPE and mul-
tiscale computational fluid dynamics (CFD) for result comparisons. The PSCOPE model
consists of a hydraulic experiment representing a stenosis in the inferior vena cava (IVC)
coupled to the LPN physiology model (Figure B.2a). Correspondingly, a computational
fluid dynamic simulation of the identical stenosis geometry coupled to the same location in
the same physiology model (Figure B.2b) provides the reference data for verification. Test
cases involving stenosis levels (by area reduction) of 60% and 85% and simulated phys-
iologies of 1 and 5 metabolic equivalent (MET) are used to demonstrate the PSCOPE’s
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ability to model different combinations of physical experiments and physiology simulations.
The detailed 3D geometries of the 60% and 85% area obstructions used in the verification
experiments are shown in Figure B.1; each geometry has a patent diameter of 19 mm rep-
resenting an extra-cardiac conduits implemented during the Fontan surgical operation [27]
and contains a lengthy portion downstream of the stenosis to capture the complex flow and
the dissipation of vortices shed by the stenosis.
To conduct the PSCOPE, we physically reproduce the 3D geometries using a high-
resolution 3D-printer (Connex 350 PolyJet, Stratasys, Inc., Eden Prairie, MN) and rigid
material (VeroClear, Stratasys, Inc., Eden Prairie, MN). We performed flow experiment,
data collection, and data processing using each physical phantom as described in the Sup-
plemental Materials on the ASME Digital Collection; each flow experiment is coupled to
the Fontan physiology simulations representing 1 and 5 MET.
For the multiscale simulations, each 3D geometry is discretized spatially heteroge-
neously (with different zones as shown in Figure B.1) into a finite element mesh containing
linear tetrahedral elements using meshing software (meshsim, Simmetrix, Inc., New York,
NY) [28]. The resulting meshes contain a total of 11.1×106 and 11.8×106 elements for the
85% and 60% stenosis geometries, respectively. Comparing to a previous numerical study
investigating stenosis of similar dimensions and Reynolds number [29], the meshes we em-
ploy contain numbers of elements that are one order of magnitude higher (see Table B.2).
All of the simulations utilize a time-step size of 0.001s. We have included a mesh density
and time-step size analysis. A no-slip boundary condition is applied to the vessel wall of
the geometries; pressures from the physiology simulations are coupled to the finite element
model at the inlet and outlet faces as Neumann boundary conditions. A Newtonian fluid
with density and dynamic viscosity as measured in the PSCOPE experiment is prescribed
in the simulations. The 3D solver utilizes a previously validated stabilized finite element
method [30–32] to solve the incompressible Navier-Stokes equations. Four and five respira-
tion cycles are simulated for the 1 MET and 5 MET cases, respectively; and the results from
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the last respiration cycle (after stabilized periodicity) are used for analysis. The NRMSE
of the pressure drop waveforms across the 3D geometry between the last and second last
cycles are <0.6% in all cases, confirming that stable periodicity is achieved.
B.2 CFD simulation timestep size and mesh density analysis
We investigated the sensitivity of the CFD results to the timestep size prescription
and the density of the mesh used for the simulations. This investigation was performed
using the 60% stenosis geometry and a constant pressure drop of 6.5mmHg from the inlet
to the outlet of the geometry, which corresponds to the peak pressure drop under the 5 MET
condition in our study. We ran each simulation until the flowrate stabilized and averaged
the last 100 timesteps to obtain the flowrate results. For the timestep size analysis, we
halved the timestep size (0.5ms) from the reference (1ms used for the PSCOPE verification
simulations) and found that the NRMSE in flowrate difference was 0.5%. For the mesh
density analysis, we used a larger mesh with 22.6×106 elements (compared to the reference
of 11.8×106 elements[4]); the NRMSE in flowrate difference between the larger mesh and
the reference mesh was 0.1%.
B.3 Verification Results
In all cases of the verification experiments, the PSCOPE achieved 1-6% final residual
after 5–10 iterations (Table B.1).
Results from the multiscale simulation show that, under the most severe flow con-
dition (the peak flow time point at 5 MET in the 85% stenosis case), the peak normalized
vorticity at the outlet have recovered to similar magnitudes as those at the inlet (Figure
B.3), suggesting that the length of the 3D geometry downstream of the stenosis is sufficient
for capturing the dissipation of vortices shed by the stenosis. Comparing results from the
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Table B.1: Final residual and number of iterations of the PSCOPE execution for the veri-
fication test cases.
MET 60% stenosis case 85% stenosis case
1 Final residual 6.12% 2.04%
Number of iterations 7 9
5 Final residual 2.71% 1.19%
Number of iterations 10 5
PSCOPE to those from the multiscale simulations, the NRMSE of important physiologic
parameters including the IVC flow, pulmonary pressure, and ventricular pressure and vol-
ume waveforms range between 0.1% and 2.1% in all test cases (Figure B.4). The NRMSE
of the pressure drop across the 3D geometry (∆P) is 0.6-5.7%, with the 60% stenosis case
exhibiting the higher NRMSE due to the signal amplitude being very low; the absolute
RMSE of ∆P in the 60% stenosis case are 0.07 mmHg and 0.44 mmHg for 1 and 5 MET,
respectively.
Through verification against established multiscale modeling results, we confirm that
the coupling method we propose for the PSCOPE indeed produces a closed-loop integra-
tion of the experimental and computational domains. The verification setup is specifically
designed to pose a challenging scenario: the physical experiment represents a part of the
venous circulation where the hydraulic signals are small and must be highly precise, and
the physiology model contains a sophisticated lumped-parameter network with closed-loop
cardiac dynamics. The verification result demonstrates that the practical implementation
of PSCOPE can achieve high accuracy in these challenging and physiologically realistic
scenarios.
79
Figure B.1: Physiology simulation coupled experiment verification and example application
setup. Hour-glass symbol denotes the insertion location where either a physical experiment
((a) and (c)) or a CFD simulation (b) is coupled to the lumped-parameter circuit physiology
model of the single-ventricle circulation. ((a) and (b)) Verification of the PSCOPE against
multiscale CFD simulations. Flow through a stenosis geometry is replicated in a hydraulic
experiment (a) and simulated by CFD (b), resulting in a PSCOPE model and a multiscale
simulation, respectively. (c) An application of the PSCOPE modeling a scenario where a
Jarvik 2000 blood pump device is implemented for cavopulmonary support.
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Figure B.2: Physiology simulation coupled experiment verification and example application
setup. Hour-glass symbol denotes the insertion location where either a physical experiment
((a) and (c)) or a CFD simulation (b) is coupled to the lumped-parameter circuit physiology
model of the single-ventricle circulation. ((a) and (b)) Verification of the PSCOPE against
multiscale CFD simulations. Flow through a stenosis geometry is replicated in a hydraulic
experiment (a) and simulated by CFD (b), resulting in a PSCOPE model and a multiscale
simulation, respectively. (c) An application of the PSCOPE modeling a scenario where a
Jarvik 2000 blood pump device is implemented for cavopulmonary support.
Table B.2: Finite element mesh size comparisons A comparison of the finite element meshes
used in this study versus one used in a previously published numerical study exhibiting
similar geometrical dimensions and flow conditions[5]. The numbers of elements of the
meshes used in this study are larger by approximately one order of magnitude.
Geometry Goubergrits et al.[5] 60% Stenosis 85% Stenosis
No. of Elements 1.3×106 11.8×106 11.1×106
Degree of Stenosis (%) 47 60 85
Patent Diameter (mm) 17.2 19 19
Length (mm) 240 172.2 168.4
Reynolds Number at Inlet 3800 3311 2020
Reynolds Number at Stenosis 7700 5183 5433
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Figure B.3: Vorticity results at the peak flow time point from multiscale CFD simulation
modeling the 85% IVC stenosis at 5 MET physiology. The maximum normalized vorticity
is the maximum vorticity at the slice location normalized to that at the inlet.
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Figure B.4: (a) 60% stenosis cases and (b) 85% stenosis cases. Physiologies of 1 and 5 MET
are distinguished by different colored lines. Solid and dashed lines represent PSCOPE
and multiscale simulation results. Qivc, Ppul, and ∆P represent the IVC flow, pulmonary
artery pressure, and pressure drop across the stenotic 3D geometry, respectively. The
NRMSE of important parameters demonstrates the accuracy of the PSCOPE. Data from
one respiratory cycle (four cardiac cycles) are shown.
83
Bibliography
[1] Masoud Farahmand, Minoo N. Kavarana, and Ethan O. Kung. Failing Fontan Cavopul-
monary Support: A Modeling Investigation. mar 2019.
[2] Masoud Farahmand, Minoo N. Kavarana, and Ethan Kung. Risks and Benefits of Using
a Commercially Available Ventricular Assist Device for Failing Fontan Cavopulmonary
Support: A Modeling Investigation. IEEE Transactions on Biomedical Engineering,
pages 1–1, 2019.
[3] Ethan Kung, Masoud Farahmand, and Akash Gupta. A Hybrid Experimental-
Computational Modeling Framework for Cardiovascular Device Testing. Journal of
Biomechanical Engineering, 141(5):051012, may 2019.
[4] Barry A Love. Transcatheter superior cavopulmonary anastomosis: Interesting tech-
nique, limited applicability, 2017.
[5] Ethan Kung, Giancarlo Pennati, Francesco Migliavacca, Tain-Yen Hsia, Richard Figli-
ola, Alison Marsden, and Alessandro Giardini. A simulation protocol for exercise
physiology in fontan patients using a closed loop lumped-parameter model. Journal of
biomechanical engineering, 136(8):081007, jun 2014.
[6] Silvio Cavalcanti, Gianni Gnudi, Paolo Masetti, Gian Paolo Ussia, and Carlo F Mar-
celletti. Analysis by mathematical model of haemodynamic data in the failing fontan
circulation. Physiological measurement, 22(1):209, 2001.
[7] Hideo Ohuchi, Aya Miyazaki, Jun Negishi, Yosuke Hayama, Michikazu Nakai, Kuni-
hiro Nishimura, Hajime Ichikawa, Isao Shiraishi, and Osamu Yamada. Hemodynamic
determinants of mortality after fontan operation. American heart journal, 189:9–18,
2017.
[8] Suzanne M Gilboa, Owen J Devine, James E Kucik, Matthew E Oster, Tiffany Riehle-
Colarusso, Wendy N Nembhard, Ping Xu, Adolfo Correa, Kathy Jenkins, and Ariane J
Marelli. Congenital heart defects in the united states: estimating the magnitude of the
affected population in 2010. Circulation, 134(2):101–109, 2016.
[9] Annelise C Arth, Sarah C Tinker, Regina M Simeone, Elizabeth C Ailes, Janet D
Cragan, and Scott D Grosse. Inpatient hospitalization costs associated with birth de-
84
fects among persons of all ages—united states, 2013. MMWR. Morbidity and mortality
weekly report, 66(2):41, 2017.
[10] Julien I.E Hoffman and Samuel Kaplan. The incidence of congenital heart disease.
Journal of the American College of Cardiology, 39(12):1890–1900, jun 2002.
[11] Joseph Atallah, Irina A. Dinu, Ari R. Joffe, Charlene M.T. Robertson, Reg S. Sauve,
John D. Dyck, David B. Ross, and Ivan M. Rebeyka. Two-Year Survival and Mental
and Psychomotor Outcomes After the Norwood Procedure. Circulation, 118(14):1410–
1418, sep 2008.
[12] Yves Udekem, Nimani Fernando, and Karin Plessis. Ask not what your Fontan can
do for you , ask what you can do for your Fontan ! The Journal of Thoracic and
Cardiovascular Surgery, 156(1):249–251, 2018.
[13] Joseph W. Rossano, Ronald K. Woods, Stuart Berger, J. William Gaynor, Nancy
Ghanayem, David L.S. Morales, Chitra Ravishankar, Michael E. Mitchell, Tejas K.
Shah, Claudius Mahr, James S. Tweddell, Iki Adachi, Steven Zangwill, Peter D. Wear-
den, Timothy B. Icenogle, Robert D. Jaquiss, and Jack Rychik. Mechanical support
as failure intervention in patients with cavopulmonary shunts (MFICS): Rationale and
aims of a new registry of mechanical circulatory support in single ventricle patients.
Congenital Heart Disease, 8(3):182–186, 2013.
[14] Paul Khairy, Susan M. Fernandes, John E. Mayer, John K. Triedman, Edward P.
Walsh, James E. Lock, and Michael J. Landzberg. Long-term survival, modes of death,
and predictors of mortality in patients with Fontan surgery. Circulation, 117(1):85–92,
2008.
[15] Amy L Throckmorton, James P Carr, Sharjeel A Tahir, Ryan Tate, Emily A Downs,
Sonya S Bhavsar, Yi Wu, John D Grizzard, and William B Moskowitz. Mechani-
cal cavopulmonary assistance of a patient-specific fontan physiology: numerical sim-
ulations, lumped parameter modeling, and suction experiments. Artificial organs,
35(11):1036–1047, 2011.
[16] Mark D Rodefeld, Steven H Frankel, and Guruprasad A Giridharan. Cavopulmonary
assist:(em) powering the univentricular fontan circulation. In Seminars in Thoracic and
Cardiovascular Surgery: Pediatric Cardiac Surgery Annual, volume 14, pages 45–54.
Elsevier, Elsevier Inc., jan 2011.
[17] Alexander C. Egbe, Heidi M. Connolly, William R. Miranda, Naser M. Ammash, Don-
ald J. Hagler, Gruschen R. Veldtman, and Barry A. Borlaug. Hemodynamics of Fontan
Failure: The Role of Pulmonary Vascular Disease. Circulation: Heart Failure, 10(12):1–
8, 2017.
[18] Marc Gewillig and Stephen C Brown. The fontan circulation after 45 years: update in
physiology. Heart, 102(14):1081–1086, 2016.
[19] Marc R de Leval. The Fontan circulation: a challenge to William Harvey? Nature
clinical practice. Cardiovascular medicine, 2(4):202–8, 2005.
85
[20] Y F Cheung, D J Penny, and A N Redington. Serial assessment of left ventricular
diastolic function after Fontan procedure. Heart (British Cardiac Society), 83(4):420–
4, 2000.
[21] R Kirk Riemer, Gabriel Amir, Steven H Reichenbach, and Olaf Reinhartz. Mechanical
support of total cavopulmonary connection with an axial flow pump. The Journal of
thoracic and cardiovascular surgery, 130(2):351–354, aug 2005.
[22] Amy L Throckmorton, Jugal Y Kapadia, Steven G Chopski, Sonya S Bhavsar,
William B Moskowitz, Scott D Gullquist, James J Gangemi, Christopher M Hag-
gerty, and Ajit P Yoganathan. Numerical, hydraulic, and hemolytic evaluation of an
intravascular axial flow blood pump to mechanically support fontan patients. Annals
of biomedical engineering, 39(1):324–336, jan 2011.
[23] Shuji Shimizu, Toru Kawada, Dai Une, Masafumi Fukumitsu, Michael James Turner,
Atsunori Kamiya, Toshiaki Shishido, and Masaru Sugimachi. Partial cavopulmonary
assist from the inferior vena cava to the pulmonary artery improves hemodynamics in
failing fontan circulation: a theoretical analysis. The Journal of Physiological Sciences,
66(3):249–255, may 2016.
[24] Rene´ Preˆtre, Achim Ha¨ussler, Dominique Bettex, and Michele Genoni. Right-sided
univentricular cardiac assistance in a failing fontan circulation. The Annals of thoracic
surgery, 86(3):1018–1020, 2008.
[25] Fabrizio Gandolfo, Gianluca Brancaccio, Salvatore Donatiello, Sergio Filippelli, Gi-
anluigi Perri, Enrico Iannace, Domenico D’Amario, Giuseppina Testa, Giuseppe
D’Avenio, Mauro Grigioni, and Antonio Amodeo. Mechanically Assisted Total
Cavopulmonary Connection With an Axial Flow Pump: Computational and In Vivo
Study. Artificial Organs, 40(1):43–49, jan 2016.
[26] Arianna Di Molfetta, Antonio Amodeo, Libera Fresiello, Maria Giovanna Trivella,
Roberta Iacobelli, Mara Pilati, and Gianfranco Ferrari. Simulation of ventricular,
cavo-pulmonary, and biventricular ventricular assist devices in failing f ontan. Artificial
organs, 39(7):550–558, 2015.
[27] Guruprasad A. Giridharan, Mickey Ising, Michael A. Sobieski, Steven C Koenig, Jun
Chen, Steven Frankel, and Mark D Rodefeld. Cavopulmonary Assist for the Failing
Fontan Circulation. ASAIO Journal, 60(6):707–715, 2014.
[28] K.C. Butler, J.C. Moise, and R.K. Wampler. The Hemopump-a new cardiac prothesis
device. IEEE Transactions on Biomedical Engineering, 37(2):193–196, 1990.
[29] Guruprasad Giridharan, Steven C. Koenig, Jeffrey Kennington, Michael A. Sobieski,
Jun Chen, Steven H. Frankel, and Mark D. Rodefeld. Performance evaluation of a pedi-
atric viscous impeller pump for fontan cavopulmonary assist. The Journal of Thoracic
and Cardiovascular Surgery, 145(1):249 – 257, jan 2013.
[30] Mark D Rodefeld, Jack H Boyd, Cynthia D Myers, Robert G Presson Jr, Wiltz W
Wagner Jr, and John W Brown. Cavopulmonary assist in the neonate: an alternative
86
strategy for single-ventricle palliation. The Journal of thoracic and cardiovascular
surgery, 127(3):705–711, mar 2004.
[31] Ben W. Anderson, David J. Barron, Timothy J. Jones, Linda Edwards, William Brawn,
and Oliver Stumper. Catheter takedown in the management of the acutely failing
Fontan circulation. Annals of Thoracic Surgery, 92(1):346–348, 2011.
[32] Hirofumi Saiki, Benjamin W. Eidem, Martha Grogan, and Margaret M. Redfield. In-
sights into the Failing Fontan Circulation: Impact of Dominant Ventricular Morphol-
ogy on Ventricular-Arterial Coupling in Adults with Fontan Circulation. Journal of
Cardiac Failure, 21(8):S94–S95, aug 2015.
[33] Yuki Nakamura, Toshikatsu Yagihara, Koji Kagisaki, Ikuo Hagino, and Junjiro
Kobayashi. Ventricular Performance in Long-Term Survivors After Fontan Operation.
The Annals of Thoracic Surgery, 91(1):172–180, jan 2011.
[34] Camden L. Hebson, Nancy M. McCabe, Robert W. Elder, William T. Mahle, Michael
McConnell, Brian E. Kogon, Emir Veledar, Maan Jokhadar, Robert N. Vincent, Anurag
Sahu, and Wendy M. Book. Hemodynamic Phenotype of the Failing Fontan in an Adult
Population. The American Journal of Cardiology, 112(12):1943–1947, dec 2013.
[35] James K. Kirklin, Francis D. Pagani, Robert L. Kormos, Lynne W. Stevenson, Eliz-
abeth D. Blume, Susan L. Myers, Marissa A. Miller, J. Timothy Baldwin, James B.
Young, and David C. Naftel. Eighth annual INTERMACS report: Special focus on
framing the impact of adverse events. The Journal of Heart and Lung Transplantation,
36(10):1080–1086, oct 2017.
[36] Michael Tree, Phillip M. Trusty, Timothy C. Slesnick, Ajit Yoganathan, Shriprasad
Deshpande, and Kevin Maher. In Vitro Examination of the HeartWare CircuLite
Ventricular Assist Device in the Fontan Connection. ASAIO Journal, 63(4):482–489,
2017.
[37] Nader Moazami, Kiyotaka Fukamachi, Mariko Kobayashi, Nicholas G. Smedira,
Katherine J. Hoercher, Alex Massiello, Sangjin Lee, David J. Horvath, and Randall C.
Starling. Axial and centrifugal continuous-flow rotary pumps: A translation from
pump mechanics to clinical practice. The Journal of Heart and Lung Transplantation,
32(1):1–11, jan 2013.
[38] Tyler Schmidt, David Rosenthal, Olaf Reinhartz, Kirk Riemer, Fei He, Tain-Yen Hsia,
Alison Marsden, Ethan Kung, Modeling of Congenital Hearts Alliance (MOCHA)+ In-
vestigators, et al. Superior performance of continuous over pulsatile flow ventricular
assist devices in the single ventricle circulation: A computational study. Journal of
biomechanics, 52:48–54, feb 2017.
[39] Florence Parent, Dora Bachir, Jocelyn Inamo, Franc¸ois Lionnet, Franc¸oise Driss, Gylna
Loko, Anoosha Habibi, Soumiya Bennani, Laurent Savale, Serge Adnot, Bernard
Maitre, Azzedine Ya¨ıci, Leila Hajji, Dermot S. O’Callaghan, Pierre Clerson, Robert
87
Girot, Frederic Galacteros, and Gerald Simonneau. A Hemodynamic Study of Pul-
monary Hypertension in Sickle Cell Disease. New England Journal of Medicine,
365(1):44–53, jul 2011.
[40] Po-Lin Hsu, Dongfang Wang, Cherry Ballard-Croft, Dawei Xiao, and Joseph B Zwis-
chenberger. A numerical simulation comparing a cavopulmonary assist device and va
ecmo for failing fontan support. ASAIO Journal, 63(5):604–612, 2017.
[41] Tyler B Fredenburg, Tiffanie R Johnson, and Mervyn D Cohen. The Fontan proce-
dure: anatomy, complications, and manifestations of failure. Radiographics : a review
publication of the Radiological Society of North America, Inc, 31:453–463, 2011.
[42] Douglas S. Goodin. Neurologic Complications of Aortic Disease and Surgery. In
Aminoff’s Neurology and General Medicine, pages 25–48. Elsevier, 2014.
[43] David N. Rosenthal, Alan H. Friedman, Charles S. Kleinman, Gary S. Kopf, Lynda E.
Rosenfeld, and William E. Hellenbrand. Thromboembolic Complications After Fontan
Operations. Circulation, 92(9):287–293, nov 1995.
[44] William R. Wilson, Georgia E. Greer, and Joseph D. Tobias. Cerebral venous thrombo-
sis after the Fontan procedure. The Journal of Thoracic and Cardiovascular Surgery,
116(4):661–663, oct 1998.
[45] Makoto Mori, Alfredo J Aguirre, Robert W Elder, Ali Kashkouli, Alton Brad Farris,
Ryan M Ford, and Wendy M Book. Beyond a broken heart: circulatory dysfunction
in the failing fontan. Pediatric cardiology, 35(4):569–579, apr 2014.
[46] Hideo Ohuchi. Where is the “optimal” fontan hemodynamics? Korean circulation
journal, 47(6):842–857, 2017.
[47] William R Miranda, Barry A Borlaug, Donald J Hagler, Heidi M Connolly, and Alexan-
der C Egbe. Haemodynamic profiles in adult fontan patients: associated haemodynam-
ics and prognosis. European journal of heart failure, jan 2019.
[48] David J Goldberg, Lea F Surrey, Andrew C Glatz, Kathryn Dodds, Michael L O’Byrne,
Henry C Lin, Mark Fogel, Jonathan J Rome, Elizabeth B Rand, Pierre Russo, et al.
Hepatic fibrosis is universal following fontan operation, and severity is associated with
time from surgery: a liver biopsy and hemodynamic study. Journal of the American
Heart Association, 6(5):e004809, may 2017.
[49] Phillip M Trusty, Zhenglun Wei, Jack Rychik, Pierre A Russo, Lea F Surrey, David J
Goldberg, Mark A Fogel, and Ajit P Yoganathan. Impact of hemodynamics and fluid
energetics on liver fibrosis after fontan operation. The Journal of thoracic and cardio-
vascular surgery, 156(1):267–275, jul 2018.
[50] PM. Trusty, Mike Tree, Kevin Maher, Timothy C. Slesnick, Kirk R. Kanter, Ajit P.
Yoganathan, and Shriprasad R. Deshpande. An in vitro analysis of the PediMag and
CentriMag for right-sided failing Fontan support. The Journal of Thoracic and Car-
diovascular Surgery, 158(5):1413–1421, nov 2019.
88
[51] Masoud Farahmand, Minoo Kavarana, and Ethan Kung. Target flow-pressure operat-
ing range for designing a failing fontan cavopulmonary support device. 2019.
[52] W. Bryc. The Normal Distribution: Characterizations with Applications, volume 100
of Lecture Notes in Statistics. Springer New York, New York, NY, 2012.
[53] Christina VanderPluym, Simon Urschel, and Holger Buchholz. Advanced therapies for
congenital heart disease: ventricular assist devices and heart transplantation. Canadian
Journal of Cardiology, 29(7):796–802, 2013.
[54] David Montani, Sven Gu¨nther, Peter Dorfmu¨ller, Fre´de´ric Perros, Barbara Girerd,
Gilles Garcia, Xavier Ja¨ıs, Laurent Savale, Elise Artaud-Macari, Laura C Price, et al.
Pulmonary arterial hypertension. Orphanet journal of rare diseases, 8(1):97, 2013.
[55] Shane J LaRue, David S Raymer, Brian R Pierce, Michael E Nassif, Christopher T
Sparrow, and Justin M Vader. Clinical outcomes associated with intermacs-defined
right heart failure after left ventricular assist device implantation. The Journal of
Heart and Lung Transplantation, 36(4):475–477, apr 2017.
[56] Mark Rodefeld. Cavopulmonary assist: Bridge to fontan repair of single-ventricle
circulation. The Journal of thoracic and cardiovascular surgery, 153(2):448–449, 2017.
[57] Mark Rodefeld. The fontan circulation: Time for a moon shot? The Journal of thoracic
and cardiovascular surgery, 156(1):252–253, 2018.
[58] Christopher Broda, Doris Taylor, and Iki Adachi. Progress in experimental and clinical
subpulmonary assistance for fontan circulation. The Journal of thoracic and cardio-
vascular surgery, 156(5):1949–1956, 2018.
[59] Cheng Zhou, Dongfang Wang, Francesca Condemi, Guangfeng Zhao, Stephen Topaz,
Cherry Ballard-Croft, and Joseph B Zwischenberger. Avalonelite double lumen cannula
for total cavopulmonary assist in failing fontan sheep model with valved extracardiac
conduit. Asaio Journal, 65(4):361–366, 2019.
[60] WC Patrick Lin, Matthew G Doyle, S Lucy Roche, Osami Honjo, Thomas L Forbes,
and Cristina H Amon. Computational fluid dynamic simulations of a cavopulmonary
assist device for failing fontan circulation. The Journal of thoracic and cardiovascular
surgery, mar 2019.
[61] Sonya S Bhavsar, Jugal Y Kapadia, Steven G Chopski, and Amy L Throckmorton. In-
travascular mechanical cavopulmonary assistance for patients with failing fontan phys-
iology. Artificial organs, 33(11):977–987, 2009.
[62] Sonya S Bhavsar, William B Moskowitz, and Amy L Throckmorton. Interaction of
an idealized cavopulmonary circulation with mechanical circulatory assist using an
intravascular rotary blood pump. Artificial organs, 34(10):816–827, oct 2010.
[63] Jugal Y Kapadia, Kathryn C Pierce, Amy K Poupore, and Amy L Throckmorton.
Hydraulic testing of intravascular axial flow blood pump designs with a protective cage
89
of filaments for mechanical cavopulmonary assist. ASAIO Journal, 56(1):17–23, jan
2010.
[64] Kerem Pekkan, Ibrahim Basar Aka, Ece Tutsak, Erhan Ermek, Haldun Balim, Ismail
Lazoglu, and Riza Turkoz. In vitro validation of a self-driving aortic-turbine venous-
assist device for fontan patients. The Journal of thoracic and cardiovascular surgery,
156(1):292–301, 2018.
[65] Cynthia D Myers, Jack H Boyd, Robert G Presson Jr, Palaniswamy Vijay, Aaron C
Coats, John W Brown, and Mark D Rodefeld. Neonatal cavopulmonary assist: pulsatile
versus steady-flow pulmonary perfusion. The Annals of thoracic surgery, 81(1):257–
263, 2006.
[66] Jakin N Jagani, Alexandrina Untaroiu, and Amit D Kalaria. Dual-propeller cavopul-
monary pump for assisting patients with hypoplastic right ventricle. ASAIO journal
(American Society for Artificial Internal Organs: 1992), 2019.
[67] Phillip M Trusty, Mike Tree, Doug Vincent, Jeffrey P Naber, Kevin Maher, Ajit P
Yoganathan, and Shriprasad R Deshpande. In vitro examination of the ventriflo true
pulse pump for failing fontan support. Artificial organs, 43(2):181–188, 2019.
[68] Osami Honjo, Matthew G Doyle, and Cristina H Amon. Commentary: Engineering
an optimal mechanical circulatory support system for the cavopulmonary connection.
The Journal of thoracic and cardiovascular surgery, 2019.
[69] Weiguang Yang, Irene E Vignon-Clementel, Guillaume Troianowski, V Mohan Reddy,
Jeffrey A Feinstein, and Alison L Marsden. Hepatic blood flow distribution and perfor-
mance in conventional and novel y-graft fontan geometries: a case series computational
fluid dynamics study. The Journal of thoracic and cardiovascular surgery, 143(5):1086–
1097, 2012.
[70] N Westerhof, F Bosman, C J De Vries, and A Noordergraaf. Analog studies of the
human systemic arterial tree. J Biomech, 2(2):121–143, 1969.
[71] Ethan Kung, James C Perry, Christopher Davis, Francesco Migliavacca, Giancarlo
Pennati, Alessandro Giardini, Tain-Yen Hsia, and Alison Marsden. Computational
Modeling of Pathophysiologic Responses to Exercise in Fontan Patients. Annals of
Biomedical Engineering, 43(6):1335–1347, jun 2015.
[72] Kerem Pekkan, David Frakes, Diane De Zelicourt, Carol W Lucas, W James Parks, and
Ajit P Yoganathan. Coupling pediatric ventricle assist devices to the fontan circulation:
simulations with a lumped-parameter model. ASAIO journal, 51(5):618–628, sep 2005.
[73] T Conover, A M Hlavacek, F Migliavacca, E Kung, A Dorfman, R S Figliola, T Y
Hsia, and Modeling of Congenital Hearts Alliance (MOCHA) Investigators. An inter-
active simulation tool for patient-specific clinical decision support in single-ventricle
physiology. J Thorac Cardiovasc Surg, 155(2):712–721, 2018.
90
[74] W Wu, D Pott, B Mazza, T Sironi, E Dordoni, C Chiastra, L Petrini, G Pennati,
G Dubini, U Steinseifer, S Sonntag, M Kuetting, and F Migliavacca. Fluid-Structure
Interaction Model of a Percutaneous Aortic Valve: Comparison with an In Vitro Test
and Feasibility Study in a Patient-Specific Case. Ann Biomed Eng, 44(2):590–603,
2016.
[75] G W Burgreen, J F Antaki, Z J Wu, and A J Holmes. Computational fluid dynamics
as a development tool for rotary blood pumps. Artif Organs, 25(5):336–340, 2001.
[76] Ethan Kung, Alessia Baretta, Catriona Baker, Gregory Arbia, Giovanni Biglino, Chiara
Corsini, Silvia Schievano, Irene E. Vignon-Clementel, Gabriele Dubini, Giancarlo Pen-
nati, Andrew Taylor, Adam Dorfman, Anthony M. Hlavacek, Alison L. Marsden, Tain-
Yen Hsia, and Francesco Migliavacca. Predictive modeling of the virtual Hemi-Fontan
operation for second stage single ventricle palliation: Two patient-specific cases. Jour-
nal of Biomechanics, 46(2):423–429, jan 2013.
[77] A Ceballos, I R Argueta-Morales, E Divo, R Osorio, C A Caldarone, A J Kassab,
and W M Decampli. Computational analysis of hybrid Norwood circulation with
distal aortic arch obstruction and reverse Blalock-Taussig shunt. Ann Thorac Surg,
94(5):1540–1550, 2012.
[78] L A Baloa, J R Boston, and J F Antaki. Elastance-based control of a mock circulatory
system. Ann Biomed Eng, 29(3):244–251, 2001.
[79] Shaun D. Gregory, Michael Stevens, Daniel Timms, and Mark Pearcy. Replication
of the Frank-Starling response in a mock circulation loop. Proceedings of the Annual
International Conference of the IEEE Engineering in Medicine and Biology Society,
EMBS, 2011:6825–6828, 2011.
[80] Kwan Woong Gwak, E. Brad Paden, Myounggyu D. Noh, and James F. Antaki. Fluidic
operational amplifier for mock circulatory systems. IEEE Transactions on Control
Systems Technology, 14(4):602–612, 2006.
[81] George M. Pantalos, Steven C. Koenig, Kevin J. Gillars, Guruprasad A. Giridharan,
and Dan L. Ewert. Characterization of an Adult Mock Circulation for Testing Cardiac
Support Devices. ASAIO Journal, 50(1):37–46, 2004.
[82] G Ferrari, C De Lazzari, R Mimmo, G Tosti, D Ambrosi, and K Gorczynska. A
computer controlled mock circulatory system for mono- and biventricular assist device
testing. Int J Artif Organs, 21(1):26–36, 1998.
[83] M Pillon, H Duffour, and M Jufer. In Vitro Experiments: Circulatory Assist Device
Interaction with a Virtual Cardiovascular System. Proceedings of the 14th Annual
International Conference of the IEEE-EMBS, 2:740–741, 1992.
[84] B M Hanson, M C Levesley, K Watterson, and P G Walker. Hardware-in-the-loop-
simulation of the cardiovascular system, with assist device testing application. Med
Eng Phys, 29(3):367–374, 2007.
91
[85] Ali Alazmani, David G Keeling, Peter G Walker, S Khawar Abbas, Osama Jaber, Kevin
Watterson, and Martin C Levesley. Introducing a hardware-in-the-loop simulation of
the cardiovascular system. In 2012 4th IEEE RAS & EMBS International Conference
on Biomedical Robotics and Biomechatronics (BioRob), pages 153–158. IEEE, 2012.
[86] M Darowski, M Kozarski, G Ferrari, K Zielinski, K Go´rczyn´ska, A Szczepanowski,
K J Palko, LIBERA Fresiello, and A Di Molfetta. A new hybrid (hydro-numerical)
model of the circulatory system. Bulletin of the Polish Academy of Sciences: Technical
Sciences, 61(4):993–1003, 2013.
[87] G Ferrari, C De Lazzari, M Kozarski, F Clemente, K Go´rczyn´ska, R Mimmo, E Mon-
nanni, G Tosti, and M Guaragno. A hybrid mock circulatory system: testing a proto-
type under physiologic and pathological conditions. ASAIO J, 48(5):487–494, 2002.
[88] Maciej Kozarski, Gianfranco Ferrari, Krzysztof Zielin´ski, Krystyna Go´rczyn´ska,
Krzysztof J Pa lko, Arkadiusz Tokarz, and Marek Darowski. A new hybrid electro-
numerical model of the left ventricle. Computers in biology and medicine, 38(9):979–
989, 2008.
[89] M Kozarski, P Suwalski, K Zielin´ski, K Go´rczyn´ska, B Szafron, KJ Pa lko,
R Smoczyn´ski, and M Darowski. A hybrid (hydro-numerical) circulatory model: in-
vestigations of mechanical aortic valves and a numerical valve model. Bulletin of the
Polish Academy of Sciences Technical Sciences, 63(3):605–612, 2015.
[90] Gregor Ochsner, Raffael Amacher, Alois Amstutz, Marianne Schmid Daners, Hendrik
Tevaearai, Stijn Vandenberghe, Markus J Wilhelm, and Lino Guzzella. A Novel Inter-
face for Hybrid Mock Circulations to Evaluate Ventricular Assist Devices. 60(2):507–
516, 2013.
[91] F Liang and H Liu. Simulation of hemodynamic responses to the valsalva maneuver:
an integrative computational model of the cardiovascular system and the autonomic
nervous system. J Physiol Sci, 56(1):45–65, 2006.
92
